



Patent Application
Docket No. UF-243X
Serial No. 09/648,864

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Janet L. Andres, Ph.D.
Art Unit : 1646
Applicants : Howard M. Johnson, Mustafa G. Mujtaba
Serial No. : 09/648,864
Filed : August 25, 2000
Conf. No. : 6790
For : Materials and Methods for Inhibition of IgE Production

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF HOWARD M. JOHNSON, Ph.D. UNDER 37 CFR §1.132

Sir:

I, Howard M. Johnson, Ph.D., hereby declare:

THAT, I am a co-inventor of the subject matter claimed in U.S. patent application Serial No. 09/648,864 (hereinafter the '864 application);

THAT, I have read and understood the '864 application;

THAT, I have read and understood the rejection of claims in the Office Actions mailed January 28, 2002, October 21, 2002, and May 19, 2003 in the '864 application;

AND, being thus duly qualified, do further declare:

The claims of the subject application are rejected under 35 USC §103(a) as obvious over the publications by Pene *et al.* (1988), Gruschwitz *et al.* (1993), or Kimata *et al.* (1995), and further in view of Johnson *et al.* (WO 97/39127). The Examiner asserts that the cited primary references teach the use of interferon alpha to downregulate IgE production. While acknowledging that the primary references do not teach that interferon tau can downregulate IgE production, the Examiner asserts that it would have been obvious to substitute interferon tau for interferon alpha in view of the Johnson *et al.* reference which, according to the Examiner, teaches that interferon alpha and interferon tau bind to the type I receptor and have similar

biological activities. From this, the Examiner concludes that the ordinarily skilled artisan, at the time of the subject invention, would have expected that interferon tau, like interferon alpha, would also downregulate IgE production.

I respectfully assert that type I interferons do not share all of the same biological activities and that an ordinarily skilled artisan, at the time of our invention, would not have reasonably expected that interferon tau would downregulate IgE production. One of the primary distinctions between interferon tau and other type I interferons is that there is a significant difference in the toxicity associated with interferon tau versus other interferons. Interferon tau is substantially less toxic to eukaryotic cells than interferon alpha. In my opinion, this is a qualitative difference between interferon tau and the other interferons.

There are other qualitative differences between interferon tau and other type I interferons, such as apoptosis inducing activity. In my laboratory, interferon tau was compared with human interferon alpha 2A for induction of apoptosis on the human Daudi cell line (Subramaniam *et al.*, 1998, "Type I interferon induction of the Cdk-inhibitor p21^{WAF1} is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line" *Oncogene*, Vol. 16, pp. 1885-1890). As shown in Figure 4 of the Subramaniam *et al.* publication, Daudi cells treated with interferon tau exhibited normal morphology, similar to that of untreated control cells. In contrast, exposure of Daudi cells to interferon alpha 2A, at 10-fold less concentration, produced classic morphologic changes characteristic of cellular apoptosis (McConkey *et al.*, 1996, "Signal Transduction Pathways in Apoptosis" *Stem Cells*, Vol. 14, pp. 619-631). These changes consist of membrane blebbing and nuclear fragmentation that is indicative of chromosome disruption. These results show that interferon tau does not induce cellular apoptosis under conditions where interferon alpha does induce apoptosis in a human cell line. The above described apoptosis inducing activity is an example of another qualitative, functional distinction between interferon tau and other type I interferons.

In a recent study, it was shown that interferon tau promotes a T-helper 2 (Th2) bias in suppression of autoimmune encephalomyelitis in a mouse model of multiple sclerosis (MS) (Soos *et al.*, 2002). Specifically, it was shown that oral administration of interferons alpha, beta and tau to myelin basic protein-specific T-cell receptor transgenic mice promoted secretion of

the Th2 cytokine interleukin-10 with similar efficiency. Unexpectedly, however, interferons alpha and beta also induced secretion of the T-helper 1 (Th1) cytokine interferon gamma, whereas interferon tau did not induce secretion of interferon gamma. Activation of Th1 cells, with the subsequent production of interferon gamma, can result in proinflammatory responses, which may explain some of the undesirable side effects of interferon beta treatment of multiple sclerosis. Interferon tau does not activate the Th1 arm of the T-cell system. These differences between interferons alpha, beta and tau could not have been predicted based on simple reference to receptor specificity.

Similar to interferon gamma, type I interferons have been shown to possess STAT-independent functions (Gongora *et al.*, 2000). Specifically, it has been shown that inhibition of interleukin-7-dependent B lymphopoiesis by interferon alpha or beta is unaffected in STAT-1-deficient mice. The data indicate that type I interferons can activate an alternative signaling pathway in which STAT1 is not an essential component. Although interferons are classified into groups or types, they possess aspects of unique structure such as their differences in amino acid composition. These differences could play a role in the non-STAT transcription factor function of these individual type I interferons. In particular, interferon tau contains more amino acid residues than do alpha interferons, as well as more differences in the sequence when compared to alpha interferons as a group (Bazer and Johnson, 1991). Even among alpha interferons, there are unpredictable differences in function. It has been shown recently, for example, that five subtypes of human alpha interferons exhibited different anticellular activity against chronic myelogenous leukemia cells (Yanai *et al.*, 2002). The authors state that "these data indicate *in vitro* distinctions between IFN- α subtypes that should be appreciated more in the clinic." (emphasis added)

Thus, while interferons tau and alpha (and other type I interferons) may have some similar biological activities, they also exhibit significant differences in activities. Accordingly, I respectfully submit that an ordinarily skilled artisan, at the time of our invention, could have only speculated that interferon tau would downregulate IgE production.


Accordingly, I respectfully maintain, based on my numerous years of involvement in interferon research and on the evidence presented herein, that the invention claimed in the '864 application is not obvious over the cited references.

A copy of each publication cited herein is attached to this Declaration.


The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or of any patent issuing thereon.

Further declarant sayeth naught.

Signed:


Howard M. Johnson, Ph.D.

Date:



SHORT REPORT

Type I interferon induction of the Cdk-inhibitor p21^{WAF1} is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line

Prem S Subramaniam, Pedro E Cruz, Amy C Hobeika and Howard M Johnson

Department of Microbiology and Cell Science, University of Florida, Gainesville, Florida 32611, USA

We show, in this study, that type I IFN induction of the cyclin-dependent kinase (cdk) inhibitor p21^{WAF1} in the human Burkitt lymphoma B cell-line Daudi and ensuing cell cycle arrest correlate with the terminal differentiation of these cells, and is ultimately followed by apoptosis and cell death. The expression of p21^{WAF1} paralleled the onset of G1 arrest and the reduction of surface IgM expression which was used as a marker of the differentiation response, and the IFN treated cells acquired a typical plasma cell-like morphology. The type II IFN IFN γ , which does not inhibit the growth of Daudi cells, did not induce the expression of p21^{WAF1}, nor affect the expression of surface IgM. The induction of p21^{WAF1} which paralleled the inhibition of the phosphorylation of the retinoblastoma protein, pRB, was preceded by the strong reduction in *c-myc* levels. We propose that the coupled down-regulation of *c-myc* and induction of p21^{WAF1} may be crucial to the induction of differentiation and G1 arrest in Daudi cells by type I IFN. Growth arrest and differentiation was followed by apoptosis and cell death, and was accompanied by the induction of the activity of the apoptotic ICE-family protease CPP32. G1 arrest and differentiation followed by apoptotic cell death are characteristics of terminal differentiation. Thus, our data suggest that the induction of p21^{WAF1} and G1 arrest mediated by type I IFN in Daudi cells is part of terminal differentiation response in these cells, highlighting a role for type I IFN as B cell terminal differentiation factors.

Keywords: interferon α ; p21^{WAF1}; B-cell differentiation; apoptosis; cell cycle

Members of the type I interferon family (IFN) that include IFN α , IFN β , IFN ω and IFN τ are strong antiproliferative agents that can induce G1 arrest in many cell types (Tamm *et al.*, 1987). The Burkitt lymphoma B cell-line Daudi is particularly sensitive to the antiproliferative effects of the type I IFN and has been routinely used in exploring the mechanisms of the G1 arrest induced by type I IFN.

In Daudi cells, IFN-induced G1 arrest is accompanied by several changes in proteins associated with the cell cycle that are interrelated at the molecular level. These events include reduction in expression of *c-myc* (Einat *et al.*, 1985) and cyclin D3 (Tiefenbrun, *et al.*, 1996) hypophosphorylation of pRB (Thomas *et al.*,

1991; Burke *et al.*, 1992; Kumar and Atlas, 1992; Resnitzky *et al.*, 1992; Zhang and Kumar, 1994), suppression of E2F DNA-binding activity (Melamed *et al.*, 1993) and inhibition of the activity of the cyclin-dependent kinase (cdk) cdk2 (Zhang and Kumar, 1994; Tiefenbrun *et al.*, 1996) associated with the cyclins cyclin E and cyclin A. The expression of the tyrosine phosphatase cdc25A has also been reported to be inhibited (Tiefenbrun *et al.*, 1996).

We and others have previously shown that another key cell-cycle regulatory molecule, the cdk-inhibitor p21^{WAF1}, is induced following IFN treatment of Daudi cells (Subramaniam and Johnson, 1997; Sangfelt *et al.*, 1997), and in Daudi cells increased levels of p21^{WAF1} can be found complexed with cdk2 following IFN treatment. This is accompanied by inhibition of cdk2 activity and G1 arrest.

Besides its role in regulating the cell cycle, the cdk-inhibitor p21^{WAF1} appears to play an important role in the differentiation of many cell types (reviewed in Gartel *et al.*, 1996). Cellular differentiation is preceded by G1 arrest and exit from the cell cycle. The treatment of Daudi cells with type I IFN induces many phenotypical changes characteristic of the terminal differentiation of B cells to plasma cells (Exley *et al.*, 1987a,b; Clemens *et al.*, 1988). Thus, in this study, we have further investigated the temporal relationships between p21^{WAF1} expression, molecular changes during G1 arrest and the differentiation of Daudi cells following IFN treatment.

The treatment of Daudi cells with IFN α leads to a rapid induction of the protein levels of p21^{WAF1} that was evident at 6–8 h of treatment and increased over a 20 h period (Figure 1a). The induction of p21^{WAF1} paralleled the accumulation of cells in the G1 phase of the cell cycle (Figure 1a: % of cells with 2N DNA content). Thus, there is a close link between the induction of p21^{WAF1} and G1 arrest induced by IFN α . In contrast, the type II IFN, IFN γ , had no effect on the levels of p21^{WAF1} in Daudi cells (Figure 1a) which is consistent with the fact that IFN γ does not inhibit the growth of Daudi cells (Tomita *et al.*, 1982; Rubin *et al.*, 1983; data not shown). This lack of effect of IFN γ is specific to Daudi cells since in DU145 cells, a human prostate cancer cell line, IFN γ treatment clearly induced the expression of p21^{WAF1} (Figure 1b) and also inhibited the progression of DU145 cells through the G1 phase of the cell cycle (Hobeika, *et al.*, manuscript submitted). Thus, type I IFN induction of the cdk-inhibitor p21^{WAF1} correlates with the inhibition of the cell cycle of Daudi cells in G1.

We next determined the temporal relationship of the induction of p21^{WAF1} by type I IFN to changes in other cell cycle-associated proteins. As can be seen from




Figure 1 Induction of p21^{WAF1} by IFNα in Daudi cells (a). Daudi cells at approximately 2×10^5 cells per ml were treated in complete growth medium (RPMI-1640 supplemented with 20% fetal bovine serum) with IFNα (320 U/ml), or IFNγ (400 U/ml) for the indicated time periods and p21^{WAF1} expression assayed by immunoprecipitation and immunoblotting from cell extracts as described earlier (Subramaniam and Johnson, 1997). For cell cycle analysis cell samples containing approximately 2×10^6 cells per ml were prepared and stained with propidium iodide using previously described procedures (Noguchi, 1992). Data from 50 000 recorded events were used for cell cycle analysis using the CellFIT program (Subramaniam and Johnson, 1997). (b). Effect of IFNγ treatment of DU145 cells (at 2×10^5 cells per ml) on the expression of p21^{WAF1}. Total cell extracts from treated and untreated cells were analysed by SDS-PAGE and immunoblotting. For the detection of proteins from total cell extracts, cells were lysed in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 250 mM NaCl, 2 mM EGTA, 2 mM EDTA, 50 mM NaF, 20 mM β-glycerol phosphate, 2 mM Na₃VO₄, 10–20 μg/ml each of leupeptin, pepstatin and aprotinin, 5 μg/ml of benzamide, 50 μM p-nitrophenyl guanadinobenzoate, 1% Triton-X 100, 0.25% Na-deoxycholate, 0.1% SDS and 1 mM phenylmethylsulfonyl fluoride. Approximately 80–100 μg total protein from extracts was used for subsequent SDS-PAGE and immunoblotting. α, IFNα; γ, IFNγ; τ, IFNτ

Figure 2. IFNα treatment caused a rapid reduction in the expression of *c-myc* and cyclin D3 proteins (Figure 2a and b). These events were accompanied by reduced phosphorylation of pRB, as evidenced by the increase in migration of the hypophosphorylated forms by 8 h following treatment. However, the levels of the cell cycle tyrosine phosphatase cdc25A, which activates cdk2, were not affected by IFN treatment. The changes in cyclin D3 and pRB appear to occur within a similar time frame as the induction of p21^{WAF1} and are consistent temporally with the onset of type I IFN-induced G1 arrest in Daudi cells. The reduction of *c-myc* levels appears to be the earliest event, but is closely followed by the induction of p21^{WAF1}. This




Figure 2 Effect of IFNα (320 U/ml) on the expression of various cell-cycle associated proteins in Daudi cells. (a) Equal amounts of protein, within a given experiment, from total cell extracts prepared as described in Figure 1b from untreated and IFN treated cells were subjected to SDS-PAGE and immunoblotting and membranes probed with antibodies to *c-myc*, pRB and cdc25A. The *c-myc* blot was stripped and reprobed for cyclin D3

reciprocal down-regulation of *c-myc* and induction of p21^{WAF1} and growth arrest, shown here in IFN-treated Daudi cells, is analogous to that seen in other haematopoietic cells where *c-myc* down regulation also appears to be tightly coupled to p21^{WAF1} induction and growth arrest (Steinman *et al.*, 1994; Blagosklonny *et al.*, 1996). Moreover, this inverse relationship between *c-myc* and p21^{WAF1} is also linked to the differentiation of haematopoietic cells when treated with appropriate differentiation inducing agents (Blagosklonny *et al.*, 1996). Thus, we next determined if these events were linked to the induction of differentiation of Daudi cells by type I IFN, using the characteristic loss of surface IgM expression as a marker. (Exley *et al.*, 1987a,b).

The down-regulation of surface IgM upon treatment of Daudi cells with IFNα and IFNτ occurred in a dose-response fashion (data not shown). IFNα induced a rapid down regulation of surface IgM that paralleled the induction of p21^{WAF1} and was closely linked with the induction of G1 arrest in Daudi cells (Figure 3a). Similarly, IFNτ was also able to induce a rapid decrease in surface IgM expression that was closely linked to the induction of G1 arrest (Figure 3b). In contrast, IFNγ which has no effect on the expression of p21^{WAF1} in Daudi cells did not affect the expression of surface IgM (data not shown). Thus, type I IFN induced differentiation of the Daudi cell line is associated with the induction of p21^{WAF1} and G1 arrest. Moreover, these data are consistent with the hypothesis that the coupled *c-myc* down-regulation and p21^{WAF1} induction are signals for the induction of G1 arrest and differentiation of Daudi cells following treatment with type I IFN.

To confirm that Daudi cells were indeed differentiating we examined cytospin preparations of treated and untreated cells using light microscopy. Compared to untreated cells (Figure 4a), IFNτ treated cells (Figure

4b) showed a distinct plasma cell-like morphology characterized by their large cytoplasmic volume and eccentric nuclei. With IFN α treatment, a large number of differentiated cells also appeared to have undergone changes in their nuclear structure (Figure 4c) that closely resembled cells undergoing apoptosis suggesting that the differentiation of these cells is accompanied by




Figure 3 Relationship of G1 arrest to the differentiation response induced by IFN treatment of Daudi cells. Optimal concentrations of IFN were determined from prior dose-response experiments. Data are representative of at least two independent experiments. (a) Time course of the effect IFN α on surface IgM expression, p21^{WAF1} induction and G1 arrest. Cells were treated with 320 U/ml of IFN α in each case and stained for surface IgM expression or with propidium iodide for cell cycle analysis. Cell surface expression of IgM was analysed by flow cytometry of cells that were stained directly with a FITC-conjugated anti-human IgM antibody according to previously described methods (Bertolini *et al.*, 1992). A total of 1×10^6 cells were stained for each sample with an optimal concentration of antibody that was previously determined by titration. Data from 30 000 events were gathered and analysed. Percent change in G1 cells is the difference in the percent of cells with 2N DNA content between untreated and treated samples. Data for p21^{WAF1} are from densitometric scanning of the bands in Figure 1a. (b). Time course of the effect of IFN γ on IgM expression and G1 arrest. Cells were treated with 3200 U/ml of IFN γ and analysed as above in (a)

apoptotic cell death. As described below, the differences in morphology of IFN τ and IFN α treated cells is related to the kinetics of the apoptotic response of Daudi cells to these IFN, where higher concentrations IFN τ are required to induce apoptosis in these cells compared to IFN α over the same time period. These data suggest that type I IFN induce B cell differentiation to plasma cells and ultimately apoptotic cell death.

In experiments using propidium iodide staining and flow cytometry analysis of IFN treated cells, IFN α and IFN τ , but not IFN γ , were found to induce an increase in cells with a DNA content of less than 2N, suggestive of apoptotic cell death, in a dose response fashion (data not shown). Using the more specific TUNEL assay for apoptosis in conjunction with flow cytometry the results in Figure 5a confirmed that IFN α induced apoptotic cell death in Daudi cells. The time course and dose response of the TUNEL assay paralleled that of the propidium iodide staining (data not shown), and significant apoptosis was seen in the population by 3 days with 100 U/ml of IFN. The time-course of this apoptotic effect is, however, in contrast to the early strong increase in cells with 2N DNA content seen with arrest in the G1 phase of the cell cycle (see Figure 1a). Thus, apoptotic cell death occurs after the changes in the cell cycle seen in these cells. IFN τ also induced apoptosis in Daudi cells, but much higher concentrations were required to achieve the same kinetics as IFN α (Figure 5b). This is consistent with the results depicted in Figure 4 where IFN α treated cells appeared to show more pronounced apoptotic morphology than IFN τ treated cells, and support the conclusion that apoptosis follows the acquisition of the differentiated phenotype in Daudi cells. Again, IFN γ was without effect in these assays (data not shown).

In further confirmation of these results, cells treated for 3 days with IFN α and IFN τ showed significantly elevated activity of the ICE-related protease CPP32 (Figure 5c). The family of ICE-proteases that include CPP32 are recognized as one of the key end mediators of apoptosis in mammalian cells (Patel *et al.*, 1996) and are good markers for ongoing apoptosis. Furthermore, IFN τ is a weaker inducer of the activity of CPP32 than IFN α , which is consistent with the data presented above that IFN τ induces a slower apoptotic response in Daudi cells.

In this study, we have shown that type I IFN induced an ordered cell cycle arrest, differentiation and cell death response in Daudi cells that is characteristic of the terminal differentiation of B cells. In particular, the induction of G1 arrest and differentiation are closely linked to the induction of the cdk-inhibitor p21^{WAF1} by type I IFN in Daudi cells. The type I IFN induced expression of p21^{WAF1} in Daudi cells occurs within a similar time frame as the down-regulation of c-myc and cyclin D3, and the inhibition of pRB phosphorylation, showing that these latter changes occur in parallel or in concert with the expression of p21^{WAF1} in Daudi cells, and may be important in the IFN-induced differentiation of these cells. Finally, we showed that following differentiation, continued IFN treatment of Daudi cells induces apoptotic cell death, a feature characteristic of B cell terminal differentiation.

We have previously shown that IFN α is also able to induce the expression of p21^{WAF1} in cells of the prostate

cancer cell line DU145, which do not express a functional pRB protein, and can inhibit cdk2 activity through p21^{WAF1}-cdk2 complexes (Hobeika *et al.*, 1997). The block in G1 induced by IFN in these cells is, however, leaky as the cells do progress into S phase albeit at a much slower pace than untreated cells

(Hobeika *et al.*, 1997). This supports the conclusion that in Daudi cells, which express a functional pRB protein, the type I IFN induced inhibition of phosphorylation of pRB probably co-operates with p21^{WAF1} induction in optimizing G1 arrest. On the other hand, the ability of IFN α to inhibit G1




Figure 4 Morphological features of IFN treated Daudi cells (400 \times magnification). Cells were left untreated (control) (a), or treated with 3200 U/ml of IFN γ (IFN γ treated) (b), or 320 U/ml of IFN α (IFN α treated) (c) for 48 h. Cytospin preparations of cell suspensions were stained using the LeukoStat stain (Fisher Scientific, Norcross, GA) and examined by light microscopy

progression in DU145 does suggest that other p21^{waf1}-dependent but pRB-independent mechanisms contribute to IFN-induced inhibition of growth in Daudi cells (see, for example, Dimri *et al.*, 1996).

The exact mechanisms by which type I IFN induce differentiation in Daudi cells are not known. However, the down-regulation of *c-myc* protein appears to be crucial to a successful differentiation program (Morgenbesser and DePinho, 1994), and is consistently observed in haematopoietic cells induced to differentiate by various agents (Steinman *et al.*, 1994; Blagoskonny *et al.*, 1996; Collins, 1987; Yen *et al.*, 1992). Further, in haematopoietic cells *c-myc* down regulation appears to be tightly coupled to p21^{waf1}

induction and growth arrest (Steinman *et al.*, 1994; Blagoskonny *et al.*, 1996) and p21^{waf1} is induced and accumulates in cells that are induced to undergo terminal differentiation by a number of differentiation inducing agents (reviewed in Gartel *et al.*, 1996). Moreover, the *c-myc* protein can antagonize the activity of p21^{waf1} (Hermeking *et al.*, 1995), most likely through a mechanism that is analogous to its ability to interfere with the inhibitory action on cyclin-cdk complexes of another related cdk-inhibitor p27Kip1 (Steiner *et al.*, 1995; Vlach *et al.*, 1996). Thus, the reciprocal relationship between the down-regulation of *c-myc* and upregulation of p21^{waf1} shown here is most likely important to the type I




Figure 5 TUNEL assay (a, b) for DNA strand-breaks, and ICE-protease CPP32 activity (c), during apoptosis induced by type I IFN in Daudi cells. Data are representative of at least two independent experiments. (a) Cells were treated at approximately 2×10^5 cells per ml with the indicated concentrations of IFN α . Control cells were left untreated. Apoptosis was determined by the TUNEL method using the Apoptosis Detection System from Promega (Madison, WI) and flow cytometry. The percentage of apoptotic cells represents the total percentage of FITC-positive cells in G0/G1 and FITC-positive cells with a DNA content less than 2N. (b) Apoptotic effect of IFN γ treatment as in (a) on Daudi cells. (c) Induction of CPP32 protease activity in Daudi cells by IFN treatment. Cells were treated with 500 U/ml of IFN α (IFN α), and IFN γ (IFN γ), or left untreated (control), for 72 h. Cell lysates from these cells were assayed for CPP32 protease activity using the colorimetric ApoAlert kit from Clontech (Palo Alto, CA). For assay, cell lysates were prepared from equal number of viable cells (10^6 cells per sample). Activity was assessed by using the synthetic peptide substrate, DEVD, coupled to p-nitroanilide and following release of the chromophore at 405 nm. Specificity was assessed using the synthetic peptide inhibitor of CPP32, DEVD-CHO, supplied with the kit

IFN induced growth arrest and cellular differentiation. This ability of *c-myc* to antagonize the function of cdk-inhibitors such as p21^{WAF1} has been postulated as the reason for the proliferation and immortalization of tumor cells that occurs upon activation of *c-myc* in these cells (Hermeking *et al.*, 1995). Our data show that in IFN-treated Daudi cells down-regulation of *c-myc* occurs prior to p21^{WAF1} induction, and is in fact the earliest detectable event. Since the down-regulation of *c-myc* is thought to be a differentiation signal (Steinman *et al.*, 1994; Blagoskonny *et al.*, 1996; Morgenbesser and DePinho, 1994; Collins, 1987; Yen *et al.*, 1992), the events associated with the IFN-

induced cell cycle arrest may be in response to a signal(s) for differentiation.

Acknowledgments

We gratefully acknowledge Neal Benson and Melissa Chen at the Flow Cytometry Core Facility, University of Florida, for expert assistance with flow cytometry and data acquisition and analysis. This work is supported by grants CA 69959 and CA 38587 to HMJ from the National Institutes of Health. This article is Florida Agriculture Experiment Station Journal Series No. R-06078.

References

- Bertoloni JN, Bertoloni J, Thean E and Benson EM. (1992). *J. Immunol.*, **149**, 1771–1778.
- Blagoskonny MV, Alvarez M, Fojo A and Neckers LM. (1996). *Leukemia Res.*, **20**, 101–107.
- Burke LC, Bybee A and Thomas NS. (1992). *Oncogene*, **7**, 783–788.
- Clemens MJ, Tilleray VJ, James R, Gewert DR. (1988). *J. Cell. Biochem.*, **38**, 251–259.
- Collins SJ. (1987). *Blood*, **70**, 1233–1244.
- Dimri GP, Nakanishi M, Desprez P-Y, Smith JR and Campisi J. (1996). *Mol. Cell. Biol.*, **16**, 2987–2997.
- Einat M, Resnitzky D and Kimchi A. (1985). *Nature*, **313**, 597–600.
- Exley R, Gordon J, Nathan P, Walker L and Clemens MJ. (1987a). *Int. J. Cancer.*, **40**, 53–57.
- Exley R, Gordon J and Clemens MJ. (1987b). *Proc. Natl. Acad. Sci. USA*, **84**, 6467–6470.
- Gartel AL, Serfas MS and Tyner AL. (1996). *Proc. Soc. Exp. Biol. Med.*, **213**, 138–149.
- Hermeking H, Funk JO, Reichert M, Ellwart JW and Eick D. (1995). *Oncogene*, **11**, 1409–1415.
- Hobeika A, Subramaniam PS and Johnson HM. (1997). *Oncogene*, **14**, 1165–1170.
- Kumar R and Atlas I. (1992). *Proc. Natl. Acad. Sci. USA*, **89**, 6599–6603.
- Melamed D, Tiefenbrun N, Yarden A and Kimchi A. (1993). *Mol. Cell. Biol.*, **13**, 5255–5265.
- Morgenbesser SD and DePinho RA. (1994). *Semin. Cancer Biol.*, **5**, 21–36.
- Noguchi PD. (1992). *Current Protocols in Immunology*. Vol. 1., Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W (eds). John Wiley & Sons, Inc: New York. p. 5.7.1.
- Patel T, Gores GJ and Kaufmann SH. (1996). *FASEB J.*, **10**, 587–597.
- Resnitzky D, Tiefenbrun N, Berissi H and Kimchi A. (1992). *Proc. Natl. Acad. Sci. USA*, **89**, 402–406.
- Rubin BY, Sekar V and Martimucci WA. (1983). *J. Gen. Virol.*, **64**, 1743–1748.
- Sangfelt O, Erickson S, Einhorn S and Grander G. (1997). *Oncogene*, **14**, 415–423.
- Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht J, Bartek J and Eilers M. (1995). *EMBO J.*, **14**, 4814–4826.
- Steinman RA, Hoffman B, Iro A, Guillof C, Liebermann DA and El-Houseini ME. (1994). *Oncogene*, **9**, 3389–3396.
- Subramaniam PS and Johnson HM. (1997). *J. Interferon Cytokine Res.*, **17**, 11–15.
- Tamm I, Jasny BR and Pfeffer LM. (1987). *Mechanisms of Interferon Actions*, Vol. II, LM Pfeffer (ed). CRC Press: Boca Raton, FL p. 25.
- Thomas NS, Burke LC, Bybee A and Linch DC. (1991). *Oncogene*, **6**, 317–322.
- Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI and Kimchi A. (1996). *Mol. Cell. Biol.*, **16**, 3934–3944.
- Tomita Y, Cantell K and Kutawa T. (1982). *Int. J. Cancer*, **30**, 161–165.
- Vlach J, Hennecke VJ, Alevizopolous S, Conti D and Amati B. (1996). *EMBO J.*, **15**, 6595–6604.
- Yen A, Chandler S, Forbes ME, Fung YK, T'Ang A and Pearson R. (1992). *Eur. J. Cell. Biol.*, **57**, 210–221.
- Zhang K and Kumar R. (1994). *Biochem. Biophys. Res. Comm.*, **200**, 522–528.



Signal Transduction Pathways in Apoptosis

David J. McConkey,^a Sten Orrenius^b

^aDepartment of Cell Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;

^bInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

Key Words. Apoptosis • Calcium • PKC • cAMP • Ceramide • Cyclin-dependent kinases • Endonuclease • Protease • BCL-2

Abstract. Emerging evidence indicates that apoptosis is regulated by some of the same signal transduction pathways previously implicated in other physiological cellular responses, including alterations in intracellular Ca^{2+} compartmentalization, activation of protein kinases and phosphatases, alterations in pH and oxidative stress. Interestingly, signals that promote apoptosis in one model can suppress cell death in another, indicating that cellular responses are determined by the intrinsic programming of the cell in question. This review will summarize current knowledge of the signal transduction pathways regulating apoptosis and discuss how they may be coupled to components of the molecular machinery for cell death. *Stem Cells* 1996; 14:619-631

Introduction

Apoptosis (programmed cell death) is a highly regulated process of selective cell deletion involved in development, normal cell turnover, hormone-induced tissue atrophy, cell-mediated immunity, tumor regression and a growing number of pathological disorders, typified by AIDS and Alzheimer's diseases [1, 2]. The response is characterized by a series of morphological alterations, including plasma and nuclear membrane blebbing, organelle relocation and compaction, chromatin condensation, and the formation of membrane-enclosed structures termed "apoptotic bodies" that are extruded into the extracellular milieu [2, 3].

Correspondence: Dr. David J. McConkey, Department of Cell Biology, Box 173, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

Accepted for publication August 15, 1996.

©AlphaMed Press 1066-5099/96/\$5.00/0

Uptake of this cellular debris is carefully controlled; apoptotic cells and bodies are specifically recognized and cleared by neighboring epithelial cells and professional phagocytic cells (macrophages) before their contents can be released into the extracellular milieu, thereby allowing for cell death to occur in the absence of inflammation [3].

The most familiar biochemical feature of apoptosis is endogenous endonuclease activation, resulting in the production of domain-sized large (50-300 kilobase) DNA fragments [4-6] and oligonucleosomal cleavage products commonly referred to as "DNA ladders" [7]. It appears that the smaller fragments are derived from the larger, and it has been suggested that different enzymatic activities are involved in generating each type, as evidenced by their unique cation requirements [8]. More recent work has demonstrated that a family of cysteine proteases homologous to the *Caenorhabditis elegans* (*C. elegans*) cell death gene *ced-3* and human interleukin 1 (IL-1) converting enzyme (ICE) are also critically involved in the response, as inhibitors of these enzymes block both endonuclease activation and cell death [9-15]. The most familiar of their substrates in apoptotic cells is the 116 kD polypeptide poly (ADP-ribose) polymerase (PARP), which is cleaved at a DEVD site by one or more members of the family to yield an 85 kD fragment [16, 17]. Although ICE itself does not appear to be required for most examples of apoptosis [18], another member of the family that exhibits higher homology to *ced-3*, termed "apopain" or "CPP32," appears to be more centrally involved [13, 19, 20]. Precisely how the ICE family regulates endonuclease activation and the other features of apoptosis is not known.

At the molecular level, a family of polypeptides homologous to *bcl-2* appears to play particularly important roles in regulating apoptosis. One class of homologs (including *bcl-2*, *bcl-x_L*, *mcl-1*, and several viral proteins) suppresses apoptotic cell death, while another group (*bax*, *bcl-x_s*, and *bak*) promotes apoptosis sensitivity. Korsmeyer's laboratory has provided a possible mechanistic explanation for these differential effects on apoptosis with the observation that the BCL-2 family members form dimers which can apparently impact the process in opposite fashions: BCL-2:BAX heterodimers predominate in cells that are resistant to apoptosis, whereas a preponderance of BAX:BAX homodimers has been linked to susceptibility to cell death [21]. Most importantly, overexpression of BCL-2 or BCL-X_L blocks apoptosis induced by very diverse stimuli, including growth factor withdrawal, tumor necrosis factor (TNF), engagement of the Fas antigen, ionizing radiation, oncogenes such as *myc* and chemical chemotherapeutic agents [1], strongly suggesting that they function at a downstream site within the apoptotic pathway that is proximal to the effector machinery (proteases and nuclease[s]). Moreover, as is true for the ICE proteases, the apoptosis-regulatory functions of BCL-2 and its homologs are evolutionarily conserved, as the *C. elegans* cell death suppressor *ced-9* is a structural and functional homolog of human *bcl-2* [22, 23].

Regulation by Ca²⁺

Several lines of evidence indicate that alterations in the cytosolic Ca²⁺ concentration and/or intracellular Ca²⁺ compartmentalization are involved in the regulation of apoptosis. Treatment of a variety of cell types with the endoplasmic reticular Ca²⁺ ATPase inhibitor thapsigargin or with Ca²⁺ ionophores leads to apoptosis [24-32]. Apoptosis can also be triggered in thymocytes (immature T cells) and primed mature T or B cells by antigen receptor stimulation, responses that are dependent upon sustained Ca²⁺ increases [33]. Glucocorticoid-induced apoptosis in thymocytes and certain T cell lines also involves sustained Ca²⁺ increases that are mediated via Ca²⁺ influx [34]; recent data suggest that these responses are mediated by the type 3 receptor for inositol

trisphosphate, a ubiquitous, physiologically relevant Ca²⁺ channel [35]. Furthermore, stimulation of glutamate (NMDA) receptors in neurons leads to Ca²⁺-mediated apoptosis [36], a response that may contribute to excitatory neuronal toxicity. Certain chemical toxins may also promote apoptosis by disrupting intracellular Ca²⁺ homeostasis, leading to nonphysiological Ca²⁺ increases that promote endonuclease activation and apoptotic cell death [37, 38]. Intracellular or extracellular Ca²⁺ chelators, Ca²⁺ channel blockers and calmodulin antagonists can all delay or abolish apoptosis in several model systems. In addition, overexpression of the Ca²⁺-binding protein calbindin D-28K can block apoptotic cell death in lymphocytes [39] and prostate carcinoma cells [32] and can prevent amyotrophic lateral sclerosis (ALS) IgG-mediated cytotoxicity in motoneuron hybrid cells [40]. Finally, recent work suggests that the protective effects of the anti-apoptosis oncoprotein Bcl-2 involve alterations in Ca²⁺ compartmentalization [41-43].

In other cellular systems, however, increases in cytosolic Ca²⁺ block apoptotic cell death. For example, treatment of IL-3-dependent hematopoietic cells with calcium ionophores blocks endogenous endonuclease activation and cell death following withdrawal of IL-3 [44]. In addition, calcium ionophores block apoptosis in aged neutrophils [45], and membrane depolarization, which leads to Ca²⁺ increases in neurons, can prevent apoptosis in response to withdrawal of nerve growth factor in dependent cells [46].

The cellular targets for Ca²⁺ in initiating apoptosis are diverse. Perhaps the most obvious is the endogenous endonuclease itself, which appears to be Ca²⁺-dependent in most (if not all) cell types [33]. Another important effect of elevated Ca²⁺ is transcriptional activation of the genes encoding the surface cell death receptor Fas and its ligand, which participate in an autocrine suicide loop in activated mature T cells. The observation that the immunosuppressants cyclosporine A and FK506 can inhibit Fas and Fas ligand upregulation and prevent cell death in some models [47] strongly suggests that the target of these immunosuppressants, the Ca²⁺/calmodulin-dependent protein phosphatase calcineurin, is involved in these events. Finally, our more recent work has identified a Ca²⁺-dependent nuclear serine protease as another target for Ca²⁺ [48, 49]. This protease cleaves lamin B₁ and histone H1 in

thymocytes, CLL lymphocytes, T cell hybridomas, and melanoma cell lines, and inhibitors of the protease can block endonuclease activation, suggesting that the protease directly or indirectly controls endonuclease activation.

Protein Kinase C

Much of the evidence for a role for protein kinase C (PKC) activation in apoptosis comes from studies with phorbol esters, a class of tumor promoters that act by binding to the diacylglycerol binding site on the enzyme and promoting its activation. Some studies have demonstrated that phorbol esters stimulate apoptosis in certain cell types [50-52]. It is possible that differential expression and/or activation of particular PKC isoforms is involved, as one study has shown that spontaneous apoptosis in the U-937 human myeloid line is associated with increased PKC- β and reduced PKC- ζ [53], while another group has shown that overexpression of PKC- ζ in the same cells upregulates PKC- α and PKC- β and sensitizes them to phorbol ester-induced apoptosis [51]. In addition, the selective sensitivity of a multidrug-resistant subclone of the MCF-7 human breast carcinoma to phorbol ester-induced apoptosis is associated with overexpression of PKC- α [50]. Furthermore, it has been reported that glucocorticoid-induced apoptosis in thymocytes involves selective activation and translocation of PKC- ϵ [54], and circumstantial evidence for a role for PKC- δ has emerged with the observation that it contains a possible ICE family cleavage site (QDN) and is proteolytically activated in apoptotic U937 cells exposed to ionizing radiation [55].

Other work suggests that PKC activation can also block apoptosis. Phorbol esters and other activators of PKC inhibit endonuclease activation in thymocytes [56], normal [57] and leukemic [58, 59] B cells, a human mammary adenocarcinoma cell line (BT-20) [60], human synovial cells [61], IL-3-dependent hematopoietic cells [62] and kidney epithelial cells [63]. Phorbol esters can also block TNF-mediated apoptosis, presumably due to their effects on the ceramide pathway to apoptosis [60, 64]. Moreover, many PKC antagonists can stimulate apoptosis [65, 66], and the protein kinase inhibitor staurosporine is being used widely as a "universal" trigger of apoptosis [67], although it

has not yet been determined whether or not the actions of these inhibitors, which are notoriously nonspecific, require inhibition of PKC.

cAMP

Studies of programmed cell death within the secondary palatal epithelium during palatal fusion provided some of the first direct evidence for a role for cyclic adenosine monophosphate (cAMP) in promoting apoptosis [68]. Pharmacological cAMP agonists are also known to be cytotoxic to certain lymphoid lines in vitro [69, 70], and agents that elevate cAMP stimulate DNA fragmentation typical of apoptosis in thymocytes [71, 72]. More recent work has confirmed these observations [73, 74] and extended them to a variety of other model systems, including immortalized primary granulosa cells [75, 76], human mammary carcinoma cells [77] and various normal and transformed T and B cells [78, 79]. As one would predict, cAMP-induced apoptosis involves activation of cAMP-dependent protein kinase (PKA) [71, 80] and specific protein phosphorylation changes [81]. cAMP can also synergize to promote glucocorticoid-induced apoptosis in thymocytes and lymphoid cell lines [82, 83].

However, the effects of cAMP are definitely cell context-dependent, as good evidence has also emerged demonstrating that cAMP can block apoptosis in other model systems. Perhaps the best example can be found in neurons, where cAMP has been shown to inhibit apoptosis in response to *ex vivo* culture, withdrawal of nerve growth factor, or depletion of extracellular K^+ [46, 84, 85]. cAMP also prevents spontaneous apoptosis in aged neutrophils [86], in a macrophage cell line exposed to exogenous nitric oxide [87], in ovarian follicles [88] and in T cells activated via the T cell receptor [89-91]. Ongoing work is required to determine if the same molecular targets are involved in the induction and suppression of apoptosis by cAMP.

Ceramide

Some receptors stimulate sphingomyelinase and subsequently cause the hydrolysis of sphingomyelin when they bind their ligands, leading to the release of diacylglycerol and

ceramide, each of which activates its own protein kinase cascade [92]. A great deal of recent work has demonstrated that ceramide is a fairly common trigger for the apoptosis. A rapid increase in ceramide is observed in TNF-treated fibroblasts, and addition of synthetic ceramide analogs is sufficient to reproduce all of the events observed following TNF treatment [64, 65]. Similar findings have been made in cells exposed to activating anti-Fas antibodies or Fas ligand [93, 94] or ionizing radiation [95]. Furthermore, the cancer chemotherapeutic agent daunorubicin induces ceramide synthesis via a novel mechanism [96]. Evidence has also been advanced that the Reaper cell death-associated polypeptide in *Drosophila* acts via ceramide production [97], suggesting that its actions may be evolutionarily conserved. However, it is possible that in other cases ceramide acts to suppress cell death, as has been suggested concerning neurons following nerve growth factor withdrawal [98].

Ongoing efforts are aimed at identifying the downstream targets for ceramide in apoptotic cells. Ceramide is known to activate both protein kinase(s) and phosphatase(s) which may both be important for subsequent responses [92], since ceramide-activated protein phosphatase (CAPP) has been implicated in the effects of TNF on HL-60 cells [99], and the stress-activated protein kinase (SAPK)/Jun kinase (JNK) pathway has also been implicated in the effects of TNF in more recent work [100]. The idea that Jun is involved is further supported by the observation that Jun expression is induced by ceramide and that inhibition of Jun expression prevents apoptosis [101]. Activation of Ras may function upstream of these events, as Fas engagement or exposure of cells to ceramide or TNF leads to accumulation of GTP-bound Ras (the active form), and dominant negative forms of Ras prevent Fas-, ceramide- and TNF-induced apoptosis [93, 102]. Ceramide-mediated activation of Ras leads to phosphorylation and activation of Raf1 [103], which may then link Ras to SAPK/JNK and other kinase pathways. Crosstalk between the ceramide pathway and PKC is likely to determine the outcome of ceramide signaling, as phorbol esters and diglycerides are potent inhibitors of ceramide-induced apoptosis [64, 104]. A recent report indicates that the mitogenic ceramide metabolite, sphingosine-1-phosphate, prevents ceramide-mediated apoptosis by the activation

of PKC [105]. The retinoblastoma gene product (Rb) may also dictate the cellular response to ceramide, in that it has been reported that ceramide induces dephosphorylation of Rb, thereby promoting its activation and resulting in cell cycle arrest at the G₁ stage [106]. This may prevent apoptosis, as we have shown that overexpression of Rb inhibits ceramide-induced DNA fragmentation in a human bladder carcinoma line (5637) [107].

Protein Tyrosine Kinases

Since virtually all surface receptors that promote survival of growth factor-dependent cells regulate cytoplasmic protein tyrosine kinases (PTKs), it could be predicted that PTKs play important roles in suppressing apoptosis. Direct evidence for this has come from the observation that protein tyrosine kinase antagonists can directly induce apoptosis [108] and can inhibit the action of many different survival factors in hematopoietic cells, including IL-2 and IL-3 [109], GM-CSF [110], and stem cell factor [111-114]. Additional examples outside the hematopoietic system include the actions of epidermal growth factor [115, 116] and basic fibroblast growth factor [115] on their target cells in tissues. Finally, a large body of evidence is now available demonstrating that the Abelson (ABL) tyrosine kinase suppresses apoptosis under a variety of circumstances, including growth factor withdrawal [117, 118], Fas engagement [119] and exposure of cells to cancer chemotherapeutics [120, 121]. The latter is likely to be of relevance to the emergence of drug resistance in chronic myelogenous leukemia, where a specific chromosomal translocation leads to fusion of the bcr and abl loci and activation of ABL protein tyrosine kinase function.

Like the other signaling pathways discussed in this review, PTKs have been implicated in promoting apoptosis. Ionizing radiation promotes PTK activation that appears required for apoptosis in B cells [122], and engagement of the Thy-1 [123, 124] or the CD4 or CD8 antigens [125] on CD4⁺CD8⁺ thymocytes promotes T cell receptor-mediated apoptosis via activation of the PTK p56^{lck}. Similarly, crosslinking CD19 on B cells has been reported to lead to activation of p56^{lck}

and to augment radiation-induced apoptosis in the cells [126].

Cyclin-Dependent Kinases

The growing appreciation of morphological and functional similarities between mitosis and apoptosis has led to an investigation into the potential involvement of the cell cycle kinases in the control of the latter. Molecular evidence for parallel control of the two responses can be found in the observation that Myc [127-129] and p53 [130-132] promote certain apoptotic responses and that both polypeptides are known to regulate cell cycle progression. The first evidence for the involvement of cell cycle-regulating protein kinases and phosphatases in apoptosis came from the observation that apoptosis induced by components of the lytic granules of cytotoxic T lymphocytes (most notably granzyme B/fragmentin) involves "premature" activation of p32/cdc2 [133], a cell cycle kinase that is regulated by cyclins A and B. Independent work by other laboratories has confirmed that a cyclin A-dependent protein kinase(s) is required for apoptosis mediated by Myc [134] and for apoptosis induced in S-phase arrested cells by staurosporine, caffeine, okadaic acid and TNF in HeLa cells [135]. Similarly, a cyclin B-dependent kinase(s) and/or cyclin E-dependent kinase(s) appear to be involved in DNA damage-induced apoptosis in HL-60 cells [136, 137], and cyclin B appears to be involved in apoptosis in PC-12 cells following nerve growth factor withdrawal [138]. Other work has implicated cyclin-dependent kinases 1 and 2 in the effects of a staurosporine analog in several different human leukemic T cell lines [139], and cyclin D1 has recently been implicated in neuronal cell death [140]. Interestingly, this last study showed that cyclin D-dependent apoptosis was blocked by Rb [140], suggesting that Rb may be a mechanism in the suppression of apoptosis. Precisely how these kinases are activated by the other biochemical signals for apoptosis remains the subject of active investigation.

Intracellular Acidification

Work from *Eastman's* laboratory was the first to clearly implicate alterations in intracellular pH in apoptosis. Working initially with

Chinese hamster ovary (CHO) cells, *Eastman's* laboratory found that apoptosis induced by cancer chemotherapeutics did not clearly involve alterations in intracellular Ca^{2+} concentration, but rather intracellular acidification was identified as the trigger [141]. Further efforts identified a pH-sensitive endonuclease (DNase II) as the most likely endonuclease mediating DNA fragmentation in this system [142]. In their subsequent efforts, they showed that intracellular acidification is also linked to apoptosis in HL-60 myeloid leukemia cells exposed to the topoisomerase-II-active agent etoposide [143] and in an IL-2-dependent T cell line following withdrawal of IL-2 [144]. These results have since been confirmed and extended by other laboratories [145, 146]. Cell acidification is also associated with apoptosis induced by withdrawal of G-CSF from neutrophils [147], and an acid endonuclease has been implicated in DNA fragmentation in this cell type [148]. Apoptosis induced by Fas engagement, cycloheximide, or ultraviolet irradiation in the Jurkat T cell line also involves acidification [149]. Furthermore, inhibition of apoptosis by phorbol esters in neutrophils and HL-60 cells has been linked to intracellular alkalinization due to activation of the Na^+/H^+ antiport [62, 144-146, 150]. The latter is attractive as a general mechanism for suppression of apoptosis, as the action of colony stimulating factors in hematopoietic cells is known to involve alkalinization due to activation of the Na^+/H^+ antiport. Implicit in this model is the idea that activation of the acid endonuclease is a critical event in apoptosis in certain model systems, which would imply that there are at least two distal pathways for genome fragmentation during the response (Ca^{2+} -dependent and -independent).

Oxygen Radicals

Several lines of evidence support the involvement of reactive oxygen species ("oxidative stress") in many models of apoptotic cell death [151]. Exogenous oxidants, including redox-active quinones and peroxides, trigger apoptosis in diverse cellular systems [152-154]. In general, low concentrations of the oxidant induce apoptosis, whereas higher levels trigger necrotic cell death [153, 154]. Even in cells that are not exposed to compounds with obvious

oxidant properties, the production of reactive oxygen species and depletion of cellular protein and soluble thiols is commonly linked to apoptosis [155-157]. Furthermore, a variety of different antioxidants, including thiols (i.e., N-acetylcysteine), ascorbate, vitamin E, citrate and radical spin traps, have all been shown to block apoptosis [155, 156, 158, 159]. Finally, evidence that the apoptosis suppressors BCL-2 and BCL-X_L may inhibit apoptosis via effects on intracellular redox provides additional evidence for the importance of the mechanism [157, 160, 161]. However, it should be emphasized that hypoxia-induced cell death can involve apoptosis, arguing against an invariant role for oxygen radicals in the response [162-165]. Furthermore, some forms of oxygen toxicity do not appear to involve apoptosis, regardless of the strength of stimulus [166].

Although the mechanisms underlying oxygen radical production in apoptotic cells are still not clear, recent work has supported a role for alterations in mitochondrial function [167]. A precipitous drop in mitochondrial membrane potential ($\Delta\psi_m$) precedes the formation of superoxide radicals, exposure of phosphatidylserine on the surface of cells, DNA fragmentation, and cell death in thymocytes and other cell types undergoing apoptosis [168-172]. This drop in $\Delta\psi_m$ is prevented by inhibitors of the ICE proteases and BCL-2 [168, 172], suggesting that it may represent a committed step in the process. A role for mitochondria in apoptosis is attractive, as dysregulation of mitochondrial function has been linked to Ca^{2+} elevations and intracellular acidification [167], and a large portion of BCL-2 has been localized to mitochondria [173]. Furthermore, recent work with cell-free models of apoptosis has demonstrated roles for mitochondrial fractions [174], and in particular, the mitochondrial protein cytochrome c [175], in promoting ICE family protease/CPP32 activation, PARP cleavage and endonuclease activation.

Conclusions and Future Directions

Although there is now good evidence implicating specific second messengers and protein kinases in the regulation of apoptosis in diverse model systems, their mechanisms of action are still obscure. Of primary importance for future work is to determine how they regulate the activation of the members of the ICE family (i.e.,

CPP32), and how this in turn leads to endonuclease activation and cell death. Moreover, although the apoptosis-regulatory properties of the BCL-2 family of polypeptides have been appreciated for several years, little progress has been made toward identifying their mechanisms of action; recent developments linking BCL-2 to various components of the Ras pathway may be particularly informative, as well as evidence that BCL-2 regulates Ca^{2+} compartmentalization and/or oxidative stress. Finally, it is not at all clear why signals that lead to apoptosis in one system promote cell survival in others. Presumably, this indicates that these signaling pathways lie upstream of the cell death effector machinery, and that the cellular response is dictated by the intrinsic programming of the cell. Perhaps investigating the mechanisms by which these second messengers regulate the cell cycle will also provide information on how they regulate programmed cell death.

Acknowledgments

Supported by a grant from the Leukemia Research Foundation, Inc. (to David J. McConkey) and by funds from the Swedish Medical Research Council (to Sten Orrenius).

References

- 1 Thompson, CB. Apoptosis in the pathogenesis and treatment of disease. *Science* 1995;267:1456-1462.
- 2 Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. *Int Rev Cytol* 1980;68:251-305.
- 3 Savill J, Fadok V, Henson P et al. Phagocytic recognition of cells undergoing apoptosis. *Immunol Today* 1993;14:131-136.
- 4 Oberhammer F, Wilson JW, Dive C et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. *EMBO J* 1993;12:3679-3684.
- 5 Filipinski J, Leblanc J, Youdale T et al. Periodicity of DNA folding in higher order chromatin structures. *EMBO J* 1990;9:1319-1327.
- 6 Brown DG, Sun XM, Cohen GM. Dexamethasone-induced apoptosis involves cleavage

- of DNA to large fragments prior to internucleosomal fragmentation. *J Biol Chem* 1993;268:3037-3039.
- 7 Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. *Nature* 1980;284:555-556.
 - 8 Sun XM, Cohen GM. Mg^{2+} -dependent cleavage of DNA into kilobase pair fragments is responsible for the initial degradation of DNA in apoptosis. *J Biol Chem* 1994;269:14857-14860.
 - 9 Yuan J, Shaham S, Ledoux S et al. The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 β -converting enzyme. *Cell* 1993;75:641-652.
 - 10 Wang L, Miura M, Bergeron L et al. Ich-1, an ICE/*ced-3*-related gene, encodes both positive and negative regulators of programmed cell death. *Cell* 1994;78:739-750.
 - 11 Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to *Caenorhabditis elegans* cell death protein *ced-3* and mammalian interleukin-1 β -converting enzyme. *J Biol Chem* 1994;269:30761-30764.
 - 12 Fernandes-Alnemri T, Litwack G, Alnemri ES. MCH-2, a new member of the apoptotic *ced-3*/ICE cysteine protease gene family. *Cancer Res* 1995;55:2737-2742.
 - 13 Nicholson DW, Ali A, Thornberry NA et al. Identification and inhibition of the ICE/*ced-3* protease necessary for mammalian apoptosis. *Nature* 1995;376:37-43.
 - 14 Tewari M, Quan LT, O'Rourke K et al. Yama/CPP32 β , a mammalian homolog of *ced-3*, is a crmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. *Cell* 1995;81:801-809.
 - 15 Martin SJ, Newmeyer DD, Mathias S et al. Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. *EMBO J* 1995;14:5191-5200.
 - 16 Kaufmann SH, Desnoyers S, Ottaviano Y et al. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. *Cancer Res* 1993;53:3976-3985.
 - 17 Lazebnik YA, Kaufmann SH, Desnoyers S et al. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. *Nature* 1994;371:346-347.
 - 18 Li P, Allen H, Banerjee S et al. Mice deficient in IL1 β -converting enzyme are defective in production of mature IL-1 β and resistant to endotoxic shock. *Cell* 1995;80:401-411.
 - 19 Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to *Caenorhabditis elegans* cell death protein *ced-3* and mammalian interleukin 1 β converting enzyme. *J Biol Chem* 1994;269:30761-30764.
 - 20 Tewari M, Quan LT, O'Rourke K et al. YAMA/CPP32 β , a mammalian homolog of *ced-3*, is a crmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. *Cell* 1995;81:801-809.
 - 21 Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. *Cell* 1994;79:189-192.
 - 22 Hengartner MO, Ellis RE, Horvitz HR. *Caenorhabditis elegans* gene *ced-9* protects cells from programmed cell death. *Nature* 1992;356:494-499.
 - 23 Hengartner MO, Horvitz HR. *C. elegans* cell survival gene *ced-9* encodes a functional homolog of mammalian proto-oncogene *bcl-2*. *Cell* 1994;76:665-676.
 - 24 Jiang S, Chow SC, Nicotera P et al. Intracellular Ca^{2+} signals activate apoptosis in thymocytes: studies using the Ca^{2+} ATPase inhibitor thapsigargin. *Exp Cell Res* 1994;212:84-92.
 - 25 Kaneko Y, Tsukamoto A. Thapsigargin-induced persistent intracellular calcium pool depletion and apoptosis in human hepatoma cells. *Cancer Lett* 1994;79:147-155.
 - 26 Levick V, Coffey H, D'Mello SR. Opposing effects of thapsigargin on the survival of developing cerebellar granule neurons in culture. *Brain Res* 1995;676:325-335.
 - 27 McConkey DJ, Hartzell P, Nicotera P et al. Calcium-activated DNA fragmentation kills immature thymocytes. *FASEB J* 1989;3:1843-1849.
 - 28 Wyllie AH, Morris RG, Smith AL et al. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. *J Pathol* 1984;142:67-77.
 - 29 Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. *J Immunol* 1984;132:38-42.
 - 30 Martikainen P, Isaacs J. Role of calcium in the programmed death of rat prostatic glandular cells. *Prostate* 1990;17:175-187.
 - 31 Martikainen P, Kyprianou N, Tucker RW et al. Programmed death of nonproliferating

- androgen-independent prostatic cancer cells. *Cancer Res* 1991;51:4693-4700.
- 32 Furuya Y, Lundmo P, Short AD et al. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. *Cancer Res* 1994;54:6167-6175.
 - 33 McConkey DJ, Orrenius S. The role of calcium in the regulation of apoptosis. *J Leuko Biol* 1996;59:775-783.
 - 34 McConkey DJ, Nicotera P, Hartzell P et al. Glucocorticoids activate a suicide process in thymocytes through an elevation of cytosolic Ca^{2+} concentration. *Arch Biochem Biophys* 1989;269:365-370.
 - 35 Khan AA, Soloski MJ, Sharp A et al. Lymphocyte apoptosis: mediation by increased type 3 inositol 1,4,5-trisphosphate receptor. *Science* 1996;273:503-508.
 - 36 Ankarcrona M, Dypbukt JM, Bonfoco E et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. *Neuron* 1995;15:961-973.
 - 37 McConkey DJ, Hartzell P, Duddy SK et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin kills immature thymocytes by Ca^{2+} -mediated endonuclease activation. *Science* 1988;242:256-259.
 - 38 Aw TY, Nicotera P, Manzo L et al. Tributyltin stimulates apoptosis in rat thymocytes. *Arch Biochem Biophys* 1990;283:46-50.
 - 39 Dowd DR, MacDonald PN, Komm BS et al. Stable expression of the calbindin-D28K complementary DNA interferes with the apoptotic pathway in T lymphocytes. *Mol Endocrinol* 1992;6:1843-1848.
 - 40 Ho BK, Alexianu ME, Colom LV et al. Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity. *Proc Natl Acad Sci USA* 1996;93:6796-6801.
 - 41 Baffy G, Miyashita T, Williamson JR et al. Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced BCL-2 oncoprotein production. *J Biol Chem* 1993;268:6511-6519.
 - 42 Lam M, Dubyak G, Chen L et al. Evidence that bcl-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca^{2+} fluxes. *Proc Natl Acad Sci USA* 1994;91:6569-6573.
 - 43 Marin MC, Fernandez A, Bick RJ et al. Apoptosis suppression by Bcl-2 is correlated with the regulation of nuclear and cytosolic Ca^{2+} . *Oncogene* 1996;12:2259-2266.
 - 44 Rodriguez-Tarduchy G, Collins M, Lopez-Rivas A. Regulation of apoptosis in interleukin-3-dependent hemopoietic cells by interleukin-3 and calcium ionophores. *EMBO J* 1990;9:2997-3002.
 - 45 Whyte MKB, Hardwick SJ, Meagher L et al. Transient elevations of cytosolic free calcium retard subsequent apoptosis in neutrophils in vitro. *J Clin Invest* 1993;92:446-455.
 - 46 Deckworth TL, Johnson EM, Jr. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. *J Cell Biol* 1993;123:1207-1222.
 - 47 Vignaux F, Vivier E, Malissen B et al. TCR/CD3 coupling to Fas-based cytotoxicity. *J Exp Med* 1995;181:781-786.
 - 48 Zhivotovsky B, Gahm A, Andarcrona M et al. Multiple proteases are involved in thymocyte apoptosis. *Exp Cell Res* 1995;221:404-412.
 - 49 McConkey DJ. Calcium-dependent, interleukin 1β -converting enzyme (ICE) inhibitor-insensitive degradation of lamin B1 and DNA fragmentation in isolated thymocyte nuclei. *J Biol Chem* 1996;271:22398-22406.
 - 50 deVente JE, Kukoly CA, Bryant WO et al. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. *J Clin Invest* 1995;96:1874-1886.
 - 51 deVente J, Kiley S, Garriss T et al. Phorbol ester treatment of U937 cells with altered protein kinase C content and distribution induces cell death rather than differentiation. *Cell Growth Differ* 1995;6:371-382.
 - 52 Kizaki H, Tadakuma T, Odaka C et al. Activation of a suicide process of thymocytes through DNA fragmentation by calcium ionophores and phorbol esters. *J Immunol* 1989;143:1790-1794.
 - 53 Pongracz J, Tuffley W, Johnson GD et al. Changes in protein kinase C isoenzyme expression associated with apoptosis in U937 myelomonocytic cells. *Exp Cell Res* 1995;218:430-438.
 - 54 Iwata M, Iseki R, Sato K et al. Involvement of protein kinase C-E in glucocorticoid-induced apoptosis in thymocytes. *Int Immunol* 1994;6:431-438.
 - 55 Emoto Y, Manome Y, Meinhardt G et al. Proteolytic activation of protein kinase C delta

- by an ICE-like protease in apoptotic cells. *EMBO J* 1995;14:6148-6156.
- 56 McConkey DJ, Hartzell P, Amador-Perez JF et al. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. *J Immunol* 1989;143:1801-1806.
- 57 Illera VA, Perandones CE, Stunz LL et al. Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4. *J Immunol* 1993;151:2965-2973.
- 58 McConkey DJ, Aguilar-Santelises M, Hartzell P et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. *J Immunol* 1991;146:1072-1076.
- 59 Forbes IJ, Zalewski PD, Giannakis C et al. Induction of apoptosis in chronic lymphocytic leukemia cells and its prevention by phorbol ester. *Exp Cell Res* 1992;198:367-372.
- 60 Bellomo G, Perotti M, Taddei F et al. Tumor necrosis factor α induces apoptosis in mammary adenocarcinoma cells by an increase in intracellular free Ca^{2+} concentration and DNA fragmentation. *Cancer Res* 1992;52:1342-1346.
- 61 Perotti M, Toddei F, Mirabelli F et al. Calcium-dependent DNA fragmentation in human synovial cells exposed to cold shock. *FEBS Lett* 1990;259:331-334.
- 62 Rajotte D, Haddad P, Haman A et al. Role of protein kinase C and the Na^+/H^+ antiporter in suppression of apoptosis by granulocyte macrophage colony-stimulating factor and interleukin-3. *J Biol Chem* 1992;267:9980-9987.
- 63 Koseki C, Herzinger D, Al-Awqati Z. Apoptosis in metanephric development. *J Cell Biol* 1992;119:1327-1333.
- 64 Obeid LM, Linardic CM, Karolak LA et al. Programmed cell death induced by ceramide. *Science* 1993;259:1769-1771.
- 65 Jarvis WD, Kolesnick RN, Fornari FA et al. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. *Proc Natl Acad Sci USA* 1994;91:73-77.
- 66 Jacobson MD, Weil M, Raff MC. Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. *J Cell Biol* 1996;133:1041-1051.
- 67 Weil M, Jacobson MD, Coles HS et al. Constitutive expression of the machinery for programmed cell death. *J Cell Biol* 1996;133:1053-1059.
- 68 Pratt RM, Martin GR. Epithelial cell death and cyclic AMP increase during palatal development. *Proc Natl Acad Sci USA* 1975;72:874-877.
- 69 Basile DV, Wood HN, Braun AC. Programming of cells for death under defined experimental conditions: relevance to the tumor problem. *Proc Natl Acad Sci USA* 1973;70:3055-3059.
- 70 Daniel V, Litwack G, Tomkins GM. Induction of cytolysis of cultured lymphoma cells by adenosine 3':5'-cyclic monophosphate and the isolation of resistant variants. *Proc Natl Acad Sci USA* 1973;70:76-79.
- 71 McConkey DJ, Orrenius S, Jondal M. Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. *J Immunol* 1990;145:1227-1230.
- 72 Kizaki H, Suzuki K, Tadakuma T et al. Adenosine receptor-mediated accumulation of cyclic AMP-induced T lymphocyte death through internucleosomal DNA cleavage. *J Biol Chem* 1990;265:5280-5284.
- 73 Mentz F, Mossalayi MD, Ouaz F et al. Involvement of cAMP in CD3/T cell receptor complex- and CD2-mediated apoptosis of human thymocytes. *Eur J Immunol* 1995;25:1798-1801.
- 74 Lalli E, Sassone-Corsi P, Ceredig R. Block of T lymphocyte differentiation by activation of the cAMP-dependent signal transduction pathway. *EMBO J* 1996;15:528-537.
- 75 Aharoni D, Dantes A, Oren M et al. cAMP-mediated signals as determinants for apoptosis in primary granulosa cells. *Exp Cell Res* 1995;218:271-282.
- 76 Keren-Tal I, Suh BS, Dantes A et al. Involvement of p53 expression in cAMP-mediated apoptosis in immortalized granulosa cells. *Exp Cell Res* 1995;218:283-295.
- 77 Boe R, Gjertsen BT, Doskeland SO et al. 8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma (MCF-7) line. *Br J Cancer* 1995;72:1151-1159.
- 78 Lomo J, Blomhoff HK, Beiske K et al. TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. *J Immunol* 1995;154:1634-1643.
- 79 Han Z, Chatterjee D, Early J et al. Isolation and characterization of an apoptosis-resistant variant of human leukemia IIL-60 cells that has switched expression from BCL-2 to BCL-XL. *Cancer Res* 1996;56:1621-1628.
- 80 Vintermyr OI, Gjertsen BT, Lanotte M et al. Microinjected catalytic subunit of cAMP-dependent protein kinase induces apoptosis in myeloid leukemia (IPC-81) cells. *Exp Cell Res* 1993;206:157-161.
- 81 Duprez E, Gjertsen BT, Bernard O et al. Antiapoptotic effect of heterologously

- expressed mutant R1 (Ala336-Asp) subunit of cAMP kinase I in a rat leukemia cell line. *J Biol Chem* 1993;268:8332-8340.
- 82 Gruol DJ, Campbell NF, Bourgeois S. Cyclic AMP-dependent protein kinase promotes glucocorticoid receptor function. *J Biol Chem* 1986;261:4909-4914.
 - 83 McConkey DJ, Orrenius S, Okret S et al. Cyclic AMP potentiates glucocorticoid-induced endogenous endonuclease activation in thymocytes. *FASEB J* 1993;7:580-585.
 - 84 D'Mello SR, Galli C, Ciotti T et al. Induction of apoptosis in cerebellar granule neurons by low potassium: inhibition of death by insulin-like growth factor I and cAMP. *Proc Natl Acad Sci USA* 1993;90:10989-10993.
 - 85 De A, Boyadjieva NI, Pastorcic M et al. Cyclic AMP and ethanol interact to control apoptosis and differentiation in hypothalamic beta-endorphin neurons. *J Biol Chem* 1994;269:26697-26705.
 - 86 Rossi AG, Cousin JM, Dransfield I et al. Agents that elevate cAMP inhibit human neutrophil apoptosis. *Biochem Biophys Res Commun* 1995;217:892-899.
 - 87 Messmer UK, Lapetina EG, Brune B. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is antagonized by protein kinase C- and protein kinase A-activating compounds. *Mol Pharmacol* 1995;47:757-765.
 - 88 Flaws JA, DeSanti A, Tilly KI et al. Vasoactive intestinal peptide-mediated suppression of apoptosis in the ovary: potential mechanisms of action and evidence of a conserved antiapoptogenic role through evolution. *Endocrinol* 1995;136:4351-4359.
 - 89 Lee MR, Liou ML, Yang YF et al. cAMP analogs prevent activation-induced apoptosis of T cell hybridomas. *J Immunol* 1993;151:5208-5217.
 - 90 Hoshi S, Furutani-Seiki M, Seto M et al. Prevention of TCR-mediated apoptosis by the elevation of cAMP. *Int Immunol* 1994;6:1081-1089.
 - 91 Goetzl EJ, An S, Zeng L. Specific suppression by prostaglandin E2 of activation-induced apoptosis of human CD4⁺CD8⁺ T lymphoblasts. *J Immunol* 1995;154:1041-1047.
 - 92 Hannun YA, Obeid LM. Ceramide: an intracellular signal for apoptosis. *Trends Biochem Sci* 1995;20:73-77.
 - 93 Gulbins E, Bissonnette R, Mahboubi A et al. FAS-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. *Immunity* 1995;2:341-351.
 - 94 Tepper CG, Jayadev S, Liu B et al. Role for ceramide as an endogenous mediator of Fas-induced cytotoxicity. *Proc Natl Acad Sci USA* 1995;92:8443-8447.
 - 95 Haimovitz-Friedman A, Kan CC, Ehleiter D et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. *J Exp Med* 1994;180:525-535.
 - 96 Bose R, Verheij M, Haimovitz-Friedman A et al. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. *Cell* 1995;82:405-414.
 - 97 White K, Tahaoglu E, Steller H. Cell killing by the *Drosophila* gene reaper. *Science* 1996;271:805-810.
 - 98 Ito A, Horigame K. Ceramide prevents neuronal programmed cell death induced by nerve growth factor deprivation. *J Neurochem* 1995;65:463-466.
 - 99 Wolff RA, Dobrowsky RT, Bielawska A et al. Role of ceramide-activated protein phosphatase in ceramide-mediated signal transduction. *J Biol Chem* 1994;269:19605-19606.
 - 100 Verheij M, Bose R, Lin XH et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. *Nature* 1996;380:75-79.
 - 101 Sawai H, Okazaki T, Yamamoto H et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. *J Biol Chem* 1995;270:27326-27331.
 - 102 Trent JC, McConkey DJ, Loughlin SM et al. Ras signaling in tumor necrosis factor-induced apoptosis. *EMBO J* 1996;15:4497-4505.
 - 103 Yao B, Zhang Y, Delikat S et al. Phosphorylation of Raf by ceramide-activated protein kinase. *Nature* 1995;378:307-310.
 - 104 Jarvis WD, Fornari FA, Jr., Browning JL et al. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. *J Biol Chem* 1994;269:31685-31692.
 - 105 Cuvillier O, Pirianov G, Kleuser B et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature* 1996;381:800-803.
 - 106 Dbaibo GS, Pushkareva MY, Jayadev S et al. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. *Proc Natl Acad Sci USA* 1995;92:1347-1351.
 - 107 McConkey DJ, Goodrich D, Bucana C et al. The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells. *Oncogene* 1996 (in press).

- 108 Laneuville P, Timm M, Hudson AT. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. *Cancer Res* 1994;54:1360-1366.
- 109 Otani H, Erdos M, Leonard WJ. Tyrosine kinase(s) regulate apoptosis and bcl-2 expression in a growth factor-dependent cell line. *J Biol Chem* 1993;268:22733-22736.
- 110 Yousefi S, Green DR, Blaser K et al. Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. *Proc Natl Acad Sci USA* 1994;91:10868-10872.
- 111 Yee NS, Paek I, Besmer P. Role of kit ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and Steel mutant mice. *J Exp Med* 1994;179:1777-1787.
- 112 Iemura A, Tsai M, Ando A et al. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. *Am J Pathol* 1994;144:321-328.
- 113 Caceres-Cortes J, Rajotte D, Dumouchel J et al. Product of the Steel locus suppresses apoptosis in hemopoietic cells. Comparison with pathways activated by granulocyte macrophage colony-stimulating factor. *J Biol Chem* 1994;269:12084-12091.
- 114 Abrahamson JL, Lee JM, Bernstein A. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. *Mol Cell Biol* 1995;15:6953-6960.
- 115 Tilly JL, Billig H, Kowalski KI et al. Epidermal growth factor and basic fibroblast growth factor suppress the spontaneous onset of apoptosis in cultured rat ovarian granulosa cells and follicles by a tyrosine kinase-dependent mechanism. *Mol Endocrinol* 1992;6:1942-1950.
- 116 Wu X, Fan Z, Masui H et al. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. *J Clin Invest* 1995;95:1897-1905.
- 117 Evans CA, Owen-Lynch PJ, Whetton AD et al. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. *Cancer Res* 1993;53:1735-1738.
- 118 Cortez D, Kadlec L, Prendergast AM. Structural and signaling requirements for BCL-ABL-mediated transformation and inhibition of apoptosis. *Mol Cell Biol* 1995;15:5531-5541.
- 119 McGahon AJ, Nishioka WK, Martin SJ et al. Regulation of the Fas apoptotic cell death pathway by Abl. *J Biol Chem* 1995;270:22625-22631.
- 120 Chapman RS, Whetton AD, Dive C. The suppression of drug-induced apoptosis by activation of v-ABL protein tyrosine kinase. *Cancer Res* 1994;54:5131-5137.
- 121 Chapman RS, Whetton AD, Chresta CM et al. Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase. *Mol Pharmacol* 1995;48:334-343.
- 122 Uckun FM, Tuel-Ahlgren L, Song CW et al. Ionizing radiation stimulates unidentified tyrosine-specific protein kinases in human B-lymphocyte precursors, triggering apoptosis and clonogenic cell death. *Proc Natl Acad Sci USA* 1992;89:9005-9009.
- 123 Nakashima I, Zhang YH, Rahman SM et al. Evidence of synergy between Thy-1 and CD3/TCR complex in signal delivery to murine thymocytes for cell death. *J Immunol* 1991;147:1153-1162.
- 124 Nakashima I, Pu MY, Hamaguchi H et al. Pathway of signal delivery to murine thymocytes triggered by co-crosslinking CD3 and Thy-1 for cellular DNA fragmentation and growth inhibition. *J Immunol* 1993;151:3511-3520.
- 125 McConkey DJ, Fosdick L, D'Adamio L et al. Co-receptor (CD4/CD8) engagement enhances CD3-induced apoptosis in thymocytes. Implications for negative selection. *J Immunol* 1994;153:2436-2443.
- 126 Waddick KG, Chae HP, Tuel-Ahlgren L et al. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis. *Radiat Res* 1993;136:313-319.
- 127 Shi Y, Glynn JM, Guilbert LJ et al. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. *Science* 1992;257:212-214.
- 128 Askew DS, Ashmun RA, Simmons BC et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. *Oncogene* 1991;6:1915-1922.
- 129 Evan GI, Wyllie H, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. *Cell* 1992;69:119-128.
- 130 Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. *Nature* 1993;362:849-852.
- 131 Lowe SW, Schmitt EM, Smith SW et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. *Nature* 1993;362:847-849.

- 132 Lowe SW, Ruley HE, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. *Cell* 1993;74:957-967.
- 133 Shi L, Nishioka WK, Th'ng J et al. Premature activation of p34cdc2 required for apoptosis. *Science* 1994;263:1143-1145.
- 134 Hoang AT, Cohen KJ, Barrett JF et al. Participation of cyclin A in myc-induced apoptosis. *Proc Natl Acad Sci USA* 1994;91:6875-6879.
- 135 Meikrantz W, Gisselbrecht S, Tam SW et al. Activation of cyclin A-dependent protein kinases during apoptosis. *Proc Natl Acad Sci USA* 1994;91:3754-3758.
- 136 Shimizu T, O'Connor PM, Kohn KW et al. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL-60 cells undergoing apoptosis induced by DNA damage. *Cancer Res* 1995;55:228-231.
- 137 Dou QP, An B, Yu C. Activation of cyclin E-dependent kinase by DNA damage signals during apoptosis. *Biochem Biophys Res Commun* 1995;214:771-780.
- 138 Gao CY, Zelenka PS. Induction of cyclin B and H1 kinase activity in apoptotic PC12 cells. *Exp Cell Res* 1995;219:612-618.
- 139 Wang Q, Worland PJ, Clark JL et al. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. *Cell Growth Differ* 1995;6:927-936.
- 140 Kranenburg O, van der Eb AJ, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. *EMBO J* 1994;15:46-54.
- 141 Barry MA, Eastman A. Endonuclease activation during apoptosis: the role of cytosolic Ca^{2+} and pH. *Biochem Biophys Res Commun* 1992;186:782-789.
- 142 Barry MA, Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. *Arch Biochem Biophys* 1993;300:440-450.
- 143 Barry MA, Reynolds JE, Eastman A. Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. *Cancer Res* 1993;53:2349-2357.
- 144 Li J, Eastman A. Apoptosis in an interleukin-2-dependent cytotoxic T lymphocyte cell line is associated with intracellular acidification. Role of the Na^+/H^+ antiport. *J Biol Chem* 1995;270:3203-3211.
- 145 Perez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalization suppresses lovostatin-induced apoptosis in HL-60 cells through the inactivation of a pH-dependent endonuclease. *J Biol Chem* 1995;270:6235-6242.
- 146 Rebollo A, Gomez J, de Aragon AM et al. Apoptosis induced by IL-2 withdrawal is associated with an intracellular acidification. *Exp Cell Res* 1995;218:581-585.
- 147 Gottlieb RA, Giesing HA, Zhu JY et al. Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by upregulating vacuolar H^+ ATPase. *Proc Natl Acad Sci USA* 1995;92:5965-5968.
- 148 Gottlieb RA, Giesing HA, Engler RL et al. The acid deoxyribonuclease of neutrophils: a possible participant in apoptosis-associated genome destruction. *Blood* 1995;86:2414-2418.
- 149 Gottlieb RA, Nordberg J, Skowronski E et al. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. *Proc Natl Acad Sci USA* 1996;93:654-658.
- 150 Zhu WH, Loh TT. Effects of Na^+/H^+ antiport and intracellular pH in the regulation of HL-60 cell apoptosis. *Biochem Biophys Acta* 1995;1269:122-128.
- 151 Buttke TM, Sandstrom PA. Redox regulation of programmed cell death in lymphocytes. *Free Radic Res* 1995;22:389-397.
- 152 McConkey DJ, Hartzell P, Nicotera P et al. Stimulation of endogenous endonuclease activity in hepatocytes exposed to oxidative stress. *Toxicol Lett* 1988;42:123-130.
- 153 Lennon SV, Martin SJ, Cotter TG. Induction of apoptosis (programmed cell death) in tumour cells by widely diverging stimuli. *Biochem Soc Trans* 1990;18:343-345.
- 154 Dybukt JM, Ankarcrona M, Burkitt M et al. Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells. The role of intracellular polyamines. *J Biol Chem* 1994;269:30553-30560.
- 155 Fernandez A, Kiefer J, Fosdick L et al. Oxygen radical production and thiol depletion are required for Ca^{2+} -mediated endogenous endonuclease activation in apoptotic thymocytes. *J Immunol* 1995;155:5133-5139.
- 156 Slater AF, Nobel CS, Maellaro E et al. Nitron spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis. *Biochem J* 1995;306:771-778.
- 157 Hockenbery DM, Oltvai ZN, Yin XM et al. BCL-2 functions in an antioxidant pathway to prevent apoptosis. *Cell* 1993;75:241-251.

- 158 Wolfe JT, Ross D, Cohen GM. A role for metals and free radicals in the induction of apoptosis in thymocytes. *FEBS Lett* 1994;352:58-62.
- 159 Mayer M, Noble M. N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro. *Proc Natl Acad Sci USA* 1994;91:7496-7500.
- 160 Kane DJ, Sarafian TA, Anton R et al. BCL-2 inhibition of neural death: decreased generation of reactive oxygen species. *Science* 1993;262:1274-1277.
- 161 Fang W, Rivard JJ, Ganser JA et al. BCL-XL rescues WEHI 231 B lymphocytes from oxidant mediated death following diverse apoptotic stimuli. *J Immunol* 1995;155:66-75.
- 162 Jacobson MD, Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. *Nature* 1995;374:814-816.
- 163 Shimizu S, Eguchi Y, Kosaka H et al. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-XL. *Nature* 1995;374:811-813.
- 164 Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. *Nature* 1996;379:88-91.
- 165 Muschel RJ, Bernhard EJ, Garza L et al. Induction of apoptosis at different oxygen tensions: evidence that oxygen radicals do not mediate apoptotic signaling. *Cancer Res* 1995;55:995-998.
- 166 Kazzaz JA, Xu J, Palaia TA et al. Cellular oxygen toxicity. Oxidant injury without apoptosis. *J Biol Chem* 1996;271:15182-15186.
- 167 Richter C. Pro-oxidants and mitochondrial Ca^{2+} : their relationship to apoptosis and oncogenesis. *FEBS Lett* 1993;325:104-107.
- 168 Zamzami N, Marchetti P, Castedo M et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. *J Exp Med* 1995;182:367-377.
- 169 Zamzami N, Marchetti P, Castedo M et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. *J Exp Med* 1995;181:1661-1672.
- 170 Petit PX, Lecoeur H, Zorn E et al. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. *J Cell Biol* 1995;130:157-167.
- 171 Castedo M, Macho A, Zamzami N et al. Mitochondrial perturbations define lymphocytes undergoing apoptotic depletion in vivo. *Eur J Immunol* 1995;25:3277-3284.
- 172 Castedo M, Hirsch T, Susin SA et al. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. *J Immunol* 1996;157:512-521.
- 173 Hockenbery DM, Nunez G, Millman C et al. BCL-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 1990;348:334-336.
- 174 Newmeyer DD, Farschon DM, Reed JC. Cell-free apoptosis in *Xenopus* extracts: inhibition by bcl-2 and requirement for an organelle fraction enriched in mitochondria. *Cell* 1994;79:353-364.
- 175 Liu X, Kim CN, Yang J et al. Induction of the apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. *Cell* 1996;86:147-157.

Cutting Edge: Oral Type I IFN- τ Promotes a Th2 Bias and Enhances Suppression of Autoimmune Encephalomyelitis by Oral Glatiramer Acetate¹

Jeanne M. Soos,^{2*} Olaf Stüve,[†] Sawsan Youssef,[†] Manuel Bravo,[†] Howard M. Johnson,[§] Howard L. Weiner,^{*} and Scott S. Zamvil^{3†}

IFN- τ , a novel type I IFN that possesses immunomodulatory properties, lacks toxicity normally associated with other type I IFNs. We examined the effects of oral IFN- τ alone and in combination with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE). By comparison of oral administration of IFN- α , - β , and - τ to myelin basic protein-specific TCR-transgenic mice, we demonstrate these type I IFNs promote secretion of the Th2 cytokine IL-10 with similar efficiency. Whereas IFN- α and - β induced IFN- γ secretion, a Th1 cytokine, IFN- τ did not. Oral IFN- τ alone suppressed EAE. When suboptimal doses were administered orally in combination to wild-type mice, IFN- τ and glatiramer acetate had a synergistic beneficial effect in suppression of EAE. This combination was associated with TGF- β secretion and enhanced IL-10 production. Thus, IFN- τ is a potential candidate for use as a single agent or in combination therapy for multiple sclerosis. *The Journal of Immunology*, 2002, 169: 2231–2235.

Interferon- β (1a and 1b) and glatiramer acetate (GA⁴; Copaxone, Cop1) are currently the only approved medications for treatment of relapsing-remitting multiple sclerosis (MS) (1, 2). These two classes of medications have distinct immunoregulatory characteristics. IFN- β exerts several effects in an Ag-nonspecific manner (1). Among its activities, IFN- β induces IL-10

secretion (3) and suppresses IFN- γ -inducible MHC class II up-regulation on APC (4). In contrast, GA, a synthetic basic random copolymer composed of tyrosine (Y), glutamate (E), alanine (A), and lysine (K), appears to preferentially affect T cells specific for CNS autoantigens (5), altering their Ag/MHC recognition not unlike altered peptide ligands (6, 7). GA also induces populations of GA-reactive Th2 regulatory cells that may provide bystander suppression in the CNS (8). Despite approval, IFN- β and GA are only partially effective MS treatments, and IFN- β , in particular, can be associated with significant side effects and potential toxicity, underscoring the importance for developing treatments that are more potent but also possess fewer potential side effects. Because currently available MS treatments alone are not entirely satisfactory, there is enthusiasm for testing medications in combination for enhanced efficacy (9, 10). In this regard, IFN- β and GA are currently being tested in combination in relapsing-remitting MS (10).

IFN- τ , a type I IFN first identified as a pregnancy recognition hormone in ruminants (11), possesses antiviral and immunoregulatory properties (11). Like IFN- β , IFN- τ induces T cell secretion of IL-10 and suppresses IFN- γ -inducible class II up-regulation on APC. Similar to other type I IFNs, IFN- τ is acid stable (11). However, in contrast to other type I IFNs, the biological activities of IFN- τ have not been associated with either significant side effects or toxicities (12, 13). IFN- τ was effective in the prevention of both acute and relapsing (11, 12) experimental allergic encephalomyelitis (EAE), a model for MS (14). IFN- τ also reversed ongoing relapsing EAE (15). In addition, IFN- τ was equally effective in EAE when given orally as well as parenterally (12, 13). Based upon these observations oral IFN- τ was tested in a phase I MS clinical trial (16). No toxicity was observed. Thus, because IFN- τ lacks toxicity and can be given orally, it is considered an attractive candidate for further evaluation in MS therapy.

In the present study, we evaluated the combination of oral IFN- τ and GA in EAE. First, we examined how oral IFN- τ alone influences T cell cytokine secretion in myelin basic protein (MBP)-specific TCR-transgenic mice. These mice, which contain a homogeneous population of naive MBP A₁-11-specific CD4⁺ (Th0) cells, serve as a valuable resource to test how immunomodulatory agents influence T cell activation and differentiation of CNS Ag-specific T cells. IFN- τ administration induced lymphocyte secretion of IL-4, IL-5, and IL-10 but, in contrast to IFN- α and - β , IFN- τ did not induce IFN- γ . Thus, IFN- τ supported a Th2 pattern of T cell differentiation. When administered in combination to wild-type mice at suboptimal doses, IFN- τ and GA had a synergistic beneficial effect in suppression of EAE. The combination of

*Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115; [†]Department of Neurology, University of California, San Francisco, CA 94143; [‡]Department of Neurology, Stanford Medical School, Stanford, CA 94305; [§]Department of Microbiology and Cell Science, University of Florida, Gainesville, FL 32611

Received for publication December 31, 2001. Accepted for publication June 28, 2002.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Support for this study was provided to S.S.Z. by Maisin Foundation Grant 98-416, National Institutes of Health Grant K02 NS02207, and National Multiple Sclerosis Society Grant RG 3206-A-3, to H.L.W. by National Institutes of Health Grants AI 43458 and NS 38037, to S.S.Z. and H.L.W. by the Nancy Davis Foundation, and to H.M.J. by National Institutes of Health Grant R01-CA69959. J.M.S. and O.S. were supported by fellowships from the National Multiple Sclerosis Society and S.Y. was supported by a fellowship from the Katherine McCormick Foundation.

[†]Current address: Immunology, Toxicology, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA 19406.

Address correspondence and reprint requests to Dr. Scott S. Zamvil, Department of Neurology, University of California, 521 Parnassus Avenue, C-440, San Francisco, CA 94143. E-mail address: zamvil@itsa.ucsf.edu

[†]Abbreviations used in this paper: GA, glatiramer acetate; MS, multiple sclerosis; EAE, experimental allergic encephalomyelitis; MBP, myelin basic protein.

GA and IFN- γ promoted lymphocyte secretion of TGF- β and enhanced IL-10.

Materials and Methods

Mice

PL/J MBP Ac1-11-specific TCR-transgenic female mice (17) were provided by Dr. C. A. Janeway, Jr. (New Haven, CT). PL/J female mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Experimentation was conducted at Brigham and Women's Hospital (Boston, MA) and the University of California (San Francisco, CA) with institutional approval according to the U.S. Public Health Service's *Policy on Human Care and Use of Laboratory Animals*.

Antigens

MBP was prepared from mouse brains and purity was confirmed by gel electrophoresis and amino acid analysis. MBP Ac1-11 (Ac-ASQKRPSQRHG) was synthesized and HPLC purified.

EAE induction

EAE was induced in 10- to 12-wk-old female PL/J mice using 300 μ g MBP in CFA containing 8 mg/ml H37Ra (Difco, Detroit, MI). Mice were injected on the flanks and base of the tail. A total of 400 ng of *Bordetella*

pertussis toxin (List Biologicals, Campbell, CA) was administered i.v. on days 0 and 2.

Production and purification of IFN- γ

Ovine IFN- γ gene was expressed in *Pichia pastoris* using a synthetic gene construct and purified by sequential DEAE-cellulose and hydroxypapate chromatography (12). Homogeneity was determined by SDS-PAGE and silver staining. Purified IFN- γ had a specific activity of $0.29 \pm 0.44 \times 10^7$ U/mg as measured by antiviral activity on Madin Darby bovine kidney cells. Murine IFN- α and IFN- β were obtained from Lee Biomolecular (San Diego, CA).


Administration of IFN- γ and GA

IFN- γ and GA were administered (100 μ l each, 200 μ l total volume/day) using 18-gauge feeding needles from Fisher Scientific (Norcross, GA). A total of 100 μ l PBS was administered to mice treated with IFN- γ or GA alone. Mice were treated for 30 days in experiments testing EAE suppression.

T cells, proliferation, and cytokine measurements

Spleen and lymph node cells were cultured in 96-well plates at 5×10^5 cells/well in X-vivo 20 (BioWhittaker, Walkersville, MD) and appropriate Ag concentrations. Separate CD4 $^+$ and CD8 $^+$ T cells from MBP Ac1-11-

FIGURE 1. Cytokine production by T cells from MBP Ac1-11-specific TCR-transgenic mice treated with oral IFN. *A*, IFN- α , - β , and - γ induce IL-10 secretion while IFN- α and - β , but not IFN- γ , promote IFN- γ secretion. *B*, CD4 $^+$ T cells from MBP Ac1-11-specific TCR-transgenic mice secrete IL-4, IL-5, and IL-10. Insets show cytokine secretion and proliferation by unseparated splenocytes from mice fed either IFN- γ or vehicle (PBS). Mice were fed daily with 1×10^5 U of IFN- α , IFN- β , or IFN- γ for 3 days. Splenocytes (5×10^5) were harvested 1 day after the last feeding. CD4 $^+$ and CD8 $^+$ T cells were separated as described in *Materials and Methods*. A total of 1×10^4 separated CD4 $^+$ or CD8 $^+$ T cells were cultured with 5×10^5 irradiated PL/J splenocytes and MBP Ac1-11. Cytokine secretion was measured by ELISA and proliferation by [3 H]thymidine incorporation as described in *Materials and Methods*.



specific TCR-transgenic mice were prepared by high-affinity negative selection using columns containing Ab-coated glass beads to remove B cells, monocytes, and either CD4⁺ or CD8⁺ cells (E&D Systems, Minneapolis, MN). CD4⁺ and CD8⁺ T cells were 95 and 85–90% pure, respectively, as measured by flow cytometry. For proliferation, 1×10^5 CD4⁺ or CD8⁺ T cells were cultured in the presence of 5×10^5 irradiated PLJ splenocytes, pulsed with $1 \mu\text{Ci}/\text{well}$ [³H]thymidine at 72 h, and harvested 16 h later. For cytokine measurements, culture supernatants were collected at 24 h for IL-2 measurement, 48 h for IFN- γ , IL-10, and TNF- α , 72 h for TGF- β , and 120 h for IL-4 and IL-5. Cytokines were measured by ELISA using kits from BioSource International (Camarillo, CA) as described previously (18). SE measurements for proliferation and cytokine measurements were within 10% of the mean.

Results and Discussion

The type I IFNs can induce lymphocyte secretion of the Th2 cytokine IL-10 (11). Therefore, we initially compared IFN- τ with IFN- α and - β for *in vivo* induction of IL-10. Unimmunized MBP Acl-11-specific TCR-transgenic mice, used as a source of naive MBP-specific T (Th0) cells, were fed three times with 1×10^5 U of IFN- α , IFN- β , or IFN- τ . Splenocytes, isolated 1 day after the last feeding, were stimulated with MBP Acl-11 *in vitro*. As shown in Fig. 1A, each of the three type I IFNs induced substantial IL-10 secretion. It can also be seen that IFN- τ was at least as potent as, if not more potent than, IFN- β at inducing IL-10 secretion.

It is also recognized that the type I IFNs can induce T cell secretion of the Th1 cytokine IFN- γ (11–19). In fact, it has been observed that the frequency of IFN- γ -secreting cells increases during the first 2 mo of IFN- β 1b treatment, possibly contributing to the prominent “flu-like” symptoms that MS patients commonly experience during initial treatment (19). Thus, we compared IFN- α , - β , and - τ for in vivo induction of IFN- γ . IFN- α was approximately twice as potent as IFN- β (Fig. 1*A*). In contrast, IFN- τ did not stimulate IFN- γ secretion above the level seen in control (vehicle (PBS)-fed) mice.

While the experiments described above demonstrated that IFN- γ promoted IL-10 secretion and did not induce IFN- γ , they did not establish whether IFN- γ treatment promoted secretion of other Th2 cytokines. Thus, we examined for secretion of IL-4 and IL-5 (Fig. 1*B*). Splenocytes from IFN- γ -fed MBP Acl-11 TCR-transgenic mice secreted IL-4, IL-5, and IL-10 when stimulated with MBP Acl-11 (Fig. 1*B*, insets), but reduced levels of IL-2 and IFN- γ (data not shown). Similarly, lymphocytes from IFN- γ -fed wild-type PL/J mice immunized with MBP Acl-11 or SJL/J mice immunized with encephalitogenic proteolipoprotein peptide p139-151 also secreted Th2 cytokines IL-4, IL-5, and IL-10 and reduced levels of IL-2 and IFN- γ (data not shown). To examine whether CD4 $^{+}$ or CD8 $^{+}$ cells were responsible for Th2 cytokine secretion, CD4 $^{+}$ and CD8 $^{+}$ cells were purified from IFN- γ -fed MBP Acl-11-specific TCR-transgenic mice and restimulated in the presence of fresh APC and MBP Acl-11. As shown in Fig. 1*B*, these Th2 cytokines were produced in cultures containing CD4 $^{+}$ T cells. In contrast, a lower amount of IL-5 and only minimal levels of IL-4 or IL-10 were detected in cultures containing CD8 $^{+}$ T cells. Similarly, Th2 cytokine secretion was observed in cultures containing CD4 $^{+}$, but not CD8 $^{+}$, T cells from IFN- γ -fed proteolipoprotein p139-151-immunized SJL/J mice (data not shown). Monocytes from IFN- β -treated MS patients can produce IL-10 (3, 20). Interestingly, the level of IL-10 production in cultures containing total spleen cells from IFN- γ -treated mice was similar to that observed when purified CD4 $^{+}$ T cells from IFN- γ -treated mice were restimulated with fresh APC (Fig. 1*B*). While our results did not negate the possibility that monocytes may have contributed to the secretion of IL-10, they indicate that IFN- γ -induced IL-10 secretion was driven by CD4 $^{+}$ T cells.

In a previous study, it was observed that when IFN- γ was applied in vitro at 100 or 1000 U/ml it inhibited Ag-induced proliferation by 40 or 61%, respectively (12). In contrast, while Th2 deviation was observed when IFN- γ was administered orally at 1×10^6 U and examined in vitro without additional IFN- γ , no significant inhibition of proliferation was observed in total spleen cells or in cultures containing separated CD4 $^{+}$ or CD8 $^{+}$ cells (Fig. 1B). In addition, we did not observe inhibition of proliferation in other experiments using 1×10^5 U IFN- γ or less. However, when mice were administered 1×10^6 U or higher doses in separate experiments >50% inhibition of proliferation was observed (O. Stuve, J. M. Soos, and S. S. Zamvil, unpublished observations).

To examine how IFN- γ modulates Th1 and Th2 cytokine responses in EAE, mice were immunized for EAE induction with MBP and treated with either IFN- γ or vehicle (PBS). While MBP-specific TCR-transgenic mice are quite useful for examining regulation of Th cell differentiation (17), it can be preferable to test treatment effects on EAE induced in wild-type mice, which contain a normal T cell repertoire. Cytokine production by MBP-reactive lymphocytes was examined 20 days after immunization of PL/J




FIGURE 2. Cytokine profile of mice protected from EAE by oral IFN- γ administration. Five PL/J mice immunized with native MBP for EAE induction were fed daily for 20 days with either 1×10^6 U feeding of oral IFN- γ (◆) or PBS (■) used as a control. Mice treated with IFN- γ did not show signs of clinical EAE (EAE score of 0 for the entire duration), whereas mice fed PBS developed EAE with mean severity of 2.5. Lymph node cells and spleen cells from two mice in each group were harvested on day 21, then pooled and cultured with MBP at the concentrations indicated. One of the two mice in the PBS-fed group that was used for this analysis had a clinical EAE score of 3 while the other mouse had a score of 2. Cytokine secretion was analyzed by ELISA as described in *Materials and Methods*.

Table 1. EAE protection by combination of oral IFN- γ and GA^a

Treatment	Incidence	Day of Onset	Mean Severity ^b
PBS	10/10	15.7	3.3
IFN- γ (1×10^5)	1/5	16	0.6
IFN- γ (5×10^4)	9/10	17.8	1.6
IFN- γ (10^5)	8/10	16.7	2.2
GA (100 μ g)	7/10	18.5	1.6
IFN- γ (5×10^4) + GA (100 μ g)	2/10 ^c	18.0	0.5
IFN- γ (10^5) + GA (100 μ g)	5/10	16.2	0.9

^a PL/J mice were immunized s.c. with 300 μ g MBP in CFA on day 0. A total of 400 ng pertussis toxin was administered on days 0 and 2. IFN- γ and GA were administered separately (100 μ l each; 200 μ l total) daily. A total of 100 μ l PBS was administered to mice treated with IFN- γ or GA alone. Severity was graded as follows: 0, normal; 1, loss of tail tone; 2, mild hind limb monoparesis or paraparesis; 3, moderate paraparesis or paraplegia; 4, quadraparesis; 5, moribund/death.

^b Mean maximal severity for each group.

^c A value of $p < 0.001$ ($Z = 4.4$) in comparison with IFN- γ (5×10^4 U) alone; $p < 0.005$ ($Z = 2.9$) in comparison with GA alone.

mice. At this time PBS-treated mice reached an average paralysis grade of 2.5 while mice treated with IFN- γ mice did not develop EAE (see Fig. 2). Control (PBS-treated) mice that developed EAE exhibited a classic Th1 response with production of IFN- γ and TNF- α (Fig. 2). These mice also produced robust levels of IL-2 but did not produce any detectable IL-10. In contrast, MBP-stimulated lymph node cells or splenocytes from IFN- γ -treated mice secreted substantial IL-10. Lymph node cells and splenocytes from these same mice secreted less IFN- γ , TNF- α , and IL-2. Thus, IFN- γ prevention of EAE correlated with induction of IL-10 and a concomitant reduction of the Th1 cytokines, IFN- γ , TNF- α , and IL-2.


Because IFN- γ and GA have distinct modes of action (2, 8, 11) and oral administration of either one can ameliorate EAE (13, 21), we investigated whether they could complement each other when administered in combination. In preliminary experiments various doses (1×10^5 , 5×10^4 , and 1×10^3 U) of IFN- γ were tested alone. Whereas 1×10^5 U IFN- γ protected mice from EAE, below this amount there was a dose-dependent loss in efficacy. One hundred micrograms of GA alone was also suboptimal. However, as shown in Table 1, when IFN- γ and GA were administered in combination at suboptimal doses, mice were protected. In comparison with IFN- γ (5×10^4 U) treatment alone, there was a significant

reduction ($Z = 4.4$; $p < 0.001$) in EAE incidence when mice were given combination therapy. In comparison with GA alone, combination therapy was also associated with a significant reduction ($Z = 2.6$; $p < 0.005$) in EAE incidence. These *in vivo* results indicated that these two immunomodulatory agents could function in an additive or synergistic manner.

GA can induce TGF- β secretion by CNS autoantigen-specific T cells (2, 21). Because previous studies attributed the beneficial effects of IFN- γ to production of IL-10 (11, 12, 15) and we observed that IFN- γ induced substantial quantities of IL-10, we evaluated whether the combination of suboptimal doses of oral IFN- γ and oral GA, which was effective in EAE protection, facilitated MBP-specific T cells to secrete TGF- β and IL-10. As shown in Fig. 3A, lymphocytes from MBP Acl-11 TCR-transgenic mice treated with oral GA alone produced relatively small amounts of IL-10 when stimulated with MBP. Lymphocytes isolated from TCR-transgenic mice fed IFN- γ alone produced a moderate level of IL-10. However, mice treated with suboptimal doses of oral IFN- γ and oral GA produced approximately two times the sum of the IL-10 produced by lymphocytes from mice treated with either agent alone. In contrast to oral GA, oral IFN- γ did not induce TGF- β , and the amount of TGF- β produced by MBP-specific T cells from TCR-transgenic mice treated with the combination of oral GA and oral IFN- γ was similar to that of mice treated with GA alone (see Fig. 3B). Thus, the clinically beneficial effects observed when suboptimal doses of oral IFN- γ and oral GA were administered in combination (Table 1) could have reflected enhanced IL-10 secretion as well as a potential additive or synergistic effect of both IL-10 and TGF- β secretion.

It was reported that IFN- γ could either prevent or reverse relapsing EAE (12, 15). IFN- γ also prevented superantigen-induced EAE relapses (12). Furthermore, we have observed that oral IFN- γ could suppress murine collagen-induced arthritis (J. M. Soos, H. L. Weiner, and S. S. Zamvil, unpublished observation). Thus, the beneficial anti-inflammatory properties of IFN- γ are not restricted to immune responses to CNS autoantigens but may be applicable to other organ-specific autoimmune conditions. Like other type 1 IFNs, IFN- γ induces IL-10 when given as monotherapy (11, 12, 15). The results from previous studies (12, 15) and this investigation demonstrated that the beneficial clinical effects of IFN- γ in EAE were dose dependent. Larger *in vivo* doses of IFN- γ induced

FIGURE 3. Secretion of IL-10 and TGF- β by MBP-specific TCR-transgenic mice treated with oral IFN- γ , oral GA, or a combination of oral IFN- γ and oral GA. Mice were fed daily for 3 days with PBS, IFN- γ (5×10^4 or 1×10^5 U), GA (100 μ g), or the combination of IFN- γ and GA. Splenocytes and lymph node cells, harvested 1 day after the last feeding, were cultured with MBP Acl-11 (50 μ g/ml). Cytokine secretion was analyzed by ELISA as described in *Materials and Methods*.



higher levels of IL-10 by Ag-reactive T cells examined in vitro. However, IL-10 may not be solely responsible for the clinical efficacy of IFN- γ . For example, it is also known that IFN- γ suppresses IFN- γ -inducible MHC class II up-regulation (11) and, as we have shown, IFN- γ also promotes secretion of IL-4 and IL-5. Thus, it is possible that these other immunoregulatory characteristics of IFN- γ may also contribute to its beneficial effects.

Previously, it was reported that administration of oral or parenteral IFN- α in combination with GA did not improve clinical EAE (22), raising concern for the safety of using GA in combination with a type I IFN. The mechanism(s) responsible for their observation was not clearly elucidated. Interestingly, an initial clinical MS trial designed to test the safety of IFN- β 1a and GA concluded that combination was safe (10). In our study we have clearly shown that the combination of oral IFN- γ and GA is beneficial in EAE. Among other differences between the earlier EAE study and this investigation is that GA was administered parenterally in their study and not orally. Most importantly, we have also demonstrated that IFN- γ , in contrast to IFN- α or IFN- β , does not promote secretion of IFN- γ , an attractive feature of this type I IFN, which could also contribute to the different clinical observations made in these two studies. This key pharmacodynamic difference between IFN- γ and IFN- α should be considered in view of the results from a recent pilot MS trial using oral IFN- α that suggested that oral IFN- α may not be effective in treatment of relapsing-remitting MS (23). In addition, patients in that trial received either 10,000 or 30,000 U of IFN- α . In contrast, in the phase I oral IFN- γ trial (16), patients were given from 4×10^7 to 3.6×10^8 antiviral units daily, without significant toxicity.

The goal of combination therapy in MS is to improve efficacy without increasing side effects (9). Thus, medications chosen for combination therapy should not have overlapping toxicities. Theoretically, these medications should produce an additive or synergistic effect. Thus, MS medications that have different modes of action, possibly acting on different parts of the pathogenic cascade, may be preferred. In this regard, IFN- γ , like IFN- β , exerts effects in an Ag-independent manner (1), whereas GA appears to affect primarily T cells specific for CNS autoantigens (6, 8). In this report, we have demonstrated for the first time that combination of a type I IFN and GA can suppress EAE. Because oral or parenteral administration of IFN- γ is effective in EAE and is not associated with significant side effects or toxicities, IFN- γ is an excellent candidate for use as a single agent or in combination in MS.

Acknowledgments

We thank Drs. C. P. Genain, S. L. Hauser, A. J. Slavin, P. A. Nelson, E. Waubant, and D. S. Goodin for helpful discussions.

References

1. Yong, V. W., S. Chabot, G. Stuve, and G. Williams. 1998. Interferon β in the treatment of multiple sclerosis: mechanisms of action. *Neurology* 51:682.

2. Neumaier, G., C. Farina, H. Wekerle, and R. Hohlfeld. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. *Neurology* 56:70.
3. Lau, Z., C. M. Peltrey, A. Cottier, J. C. Lee, and P. A. Puck. 2000. Immunomodulatory effects of interferon β 1a in multiple sclerosis. *J. Neuroimmunol.* 112:153.
4. Lu, B.-T., J. L. Riley, G. T. Babcock, M. Huston, G. R. Stark, J. M. Boss, and E. M. Ransohoff. 1995. Interferon (IFN) β acts downstream of IFN- γ -induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3- γ . *J. Exp. Med.* 182:1517.
5. Teitelbaum, D., R. Aharoni, R. Arnon, and M. Sela. 1988. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop-1. *Proc. Natl. Acad. Sci. USA* 85:9724.
6. Duda, P. W., M. C. Schmidt, S. L. Cook, J. L. Krieger, and D. A. Hafler. 2000. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. *J. Clin. Invest.* 105:967.
7. Genain, C. P., and S. S. Zamvil. 2000. Specific immunotherapy: one size does not fit all. *Nat. Med.* 6:1098.
8. Aharoni, R., D. Teitelbaum, M. Sela, and R. Arnon. 1998. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. *J. Neuroimmunol.* 91:135.
9. Kappos, L. 1996. Combinations of drugs. *Mult. Scler.* 1:400.
10. Lublin, F. G., G. Cutter, R. Elfont, C. Khar, F. L. Sak, H. McFarland, H. Panitch, J. Noseworthy, S. Reingold, J. Whitaker, et al. 2001. A trial to assess the safety of combining therapy with interferon β 1a and glatiramer acetate in patients with relapsing MS. *Neurology* 56(Suppl. 3):A148.
11. Soos, J. M., and H. M. Johnson. 1999. Interferon- γ prospects for clinical use in autoimmune disease. *BiolDrugs* 11:125.
12. Soos, J. M., P. S. Subramanian, A. C. Hobeika, J. Schifflbauer, and H. M. Johnson. 1995. The IFN pregnancy recognition hormone, IFN- γ , blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. *J. Immunol.* 155:2747.
13. Soos, J. M., G. M. Mujtaba, P. S. Subramanian, W. J. Streit, and H. M. Johnson. 1997. Oral feeding of interferon γ can prevent acute and chronic relapsing forms of experimental allergic encephalomyelitis. *J. Neuroimmunol.* 75:43.
14. Zamvil, S. S., and L. Steinman. 1990. The T lymphocyte in experimental allergic encephalomyelitis. *Annu. Rev. Immunol.* 8:579.
15. Mujtaba, M. G., W. J. Streit, and H. M. Johnson. 1998. IFN- γ suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. *Cell. Immunol.* 186:94.
16. Oles, M. J., D. J. Smith, S. L. Cook, S. J. Khoury, and H. I. Weiner. 2001. Phase I study of oral recombinant ovine interferon- γ in relapsing-remitting multiple sclerosis. *Neurology* 56(Suppl. 3):A76.
17. Hardardottir, E., J. L. Baron, and C. A. Janeway, Jr. 1995. T cells with two functional antigen-specific receptors. *Proc. Natl. Acad. Sci. USA* 92:374.
18. Slavin, A. J., J. M. Soos, G. Stuve, J. C. Patarroyo, H. I. Weiner, A. Fontana, E. K. Bikoff, and S. S. Zamvil. 2001. Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. *J. Clin. Invest.* 108:1133.
19. Dayal, A. S., M. A. Jensen, A. Lleido, and B. G. Arnason. 1995. Interferon-secreting cells in multiple sclerosis patients treated with interferon β 1b. *Neurology* 45:2173.
20. Porrim, A. M., D. Garbi, and A. T. Reder. 1995. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. *J. Neuroimmunol.* 61:27.
21. Teitelbaum, D., R. Arnon, and M. Sela. 1999. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. *Proc. Natl. Acad. Sci. USA* 96:3842.
22. Brod, S. A., J. W. Lindsey, and J. S. Wolinsky. 2000. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN- α) does not improve experimental autoimmune encephalomyelitis. *Ann. Neurol.* 47:127.
23. Brod, S. A., J. W. Lindsey, F. S. Vriesendorp, C. Abn, F. Heuninger, P. A. Narayana, and J. S. Wolinsky. 2001. Ingested IFN- α : results of a pilot study in relapsing-remitting MS. *Neurology* 57:843.

Stat-1 Is Not Essential for Inhibition of B Lymphopoiesis by Type I IFNs¹

Rafael Gongora,*[†] Robert P. Stephan,*[†] Robert D. Schreiber,[‡] and Max D. Cooper^{2*†§¶}

Type I IFNs, IFN- α , - β , and - ω , are cytokine family members with multiple immune response roles, including the promotion of cell growth and differentiation. Conversely, the type I IFNs are potent inhibitors of IL-7-dependent growth of early B lineage progenitors, effectively aborting further B lineage differentiation at the pro-B cell stage. Type I IFNs α and β function via receptor-mediated activation of a Jak/Stat signaling pathway in which Stat-1 is functionally important, because many IFN-induced responses are abrogated in Stat-1-deficient mice. To the contrary, we show here that the inhibition of IL-7-dependent B lymphopoiesis by IFN- $\alpha\beta$ is unaffected in Stat-1-deficient mice. The present data indicate that the type I IFNs can activate an alternative signaling pathway in which neither Stat-1 nor phosphatidylinositol 3'-kinase are essential components. *The Journal of Immunology*, 2000, 165: 2362–2366.

B cell development proceeds in an orderly fashion in the bone marrow (BM)³ wherein the different differentiation stages can be characterized by the rearrangement status of the Ig genes and the expression of discriminating cell surface markers (1). In mice, the expression profiles of CD45/B220, CD43 (leukosialin), BP-1/6C3 (aminopeptidase A), and μ heavy chains allow the discrimination of pro-B cells (B220⁺CD43⁺BP-1⁻IgM⁻) and pre-B cells (B220⁺CD43⁺BP-1⁺IgM⁻) (2–4). Pre-B cells also may express a receptor formed by μ heavy chains and the surrogate light chain proteins VpreB and $\lambda 5$ (5). Productive light chain gene rearrangement occurs in postmitotic pre-B cells (6), and the subsequent expression of an IgM receptor characterizes the immature B cell (B220⁺CD43⁻BP-1⁺IgM⁺). Finally, coexpression of IgD begins when the newly formed B cells migrate to the periphery (7).

IL-7, an essential growth factor for B and T lymphopoiesis in mice (8), may also influence the rearrangement of B and TCR genes (9, 10). The IL-7 receptor is composed by the IL-7R α -chain and the common γ -chain, which is shared by the IL-2, IL-4, IL-9, and IL-15 receptors (11). In keeping with the onset of IL-7 receptor expression in pro-B cells (9), B cell development is blocked at this differentiation stage in mice deficient in either IL-7 or its receptor (12, 13).

The type I IFNs, IFN- α , - β , and - ω , are members of a family of pleiotropic cytokines that participate in antiviral responses as well as in other physiological processes, such as cell growth and dif-

ferentiation (14). In earlier studies, we found that the type I IFNs selectively inhibit IL-7 promoted growth of early B lineage and T lineage cells, whereas having no effect on cell growth induced by other cytokines (15, 16). The IFN- $\alpha\beta$ inhibition of IL-7-dependent cells or cell lines is featured by the induction of apoptosis. Because type I IFNs have been shown to be constitutively produced by resident BM macrophages (15), they could play a regulatory role in normal B cell development.

IFNs bind to their cell surface receptors to activate the Jak-Stat signaling system (17–19). Janus family kinase 1 (Jak1) and tyrosine kinase 2 (Tyk2) are closely related cytoplasmic tyrosine kinases that constitutively associate with the α - and β -chains of the type I IFN receptor (IFNAR). Receptor interaction with IFN- α or - β promotes Jak1 and Tyk2 phosphorylation of tyrosine residues and activates the signal activating and transcription factors Stat-1, Stat-2, and Stat-3. The Stat proteins thereby acquire the capacity to oligomerize whereupon they migrate into the nucleus and bind to regulatory motifs in the promoter regions of many genes to modulate their transcription (20). IL-7 signaling activates a partially overlapping Jak-Stat signaling pathway. Both the Jak1 and Jak3 kinases are activated after IL-7 receptor ligation, and these kinases phosphorylate multiple substrates, including the Stat-1 and the Stat-5 transcription factors (21). However, among the multiple components of the type I IFN activation pathway, Stat-1 appeared essential in that all IFN-induced responses originally examined were defective in *Stat-1*-deficient mice (22, 23). Nevertheless, this assumption can be questioned because alternative IFN signaling pathways have been identified (14, 20).

The inhibition of B and T lymphopoiesis by type I IFNs could reflect cross-talk between the type I IFN and IL-7 signaling pathways (15, 16). As a first step in examining this interaction, we examined the effects of IFN on IL-7-mediated B lymphopoiesis in *Stat-1*-deficient mice. Contrary to our expectation, *Stat-1* does not appear to be essential for the IFN inhibition of IL-7-promoted B lymphopoiesis.

Materials and Methods

Abs and immunofluorescence flow cytometry

FITC-labeled mAbs to S7/CD43, Sca-1 and IgD, PE-labeled Abs to B220 and BP-1, CyChrome-labeled Abs to CD19 and μ heavy chains, and biotin-labeled Abs to the IL-7R α -chain were obtained from Pharmingen (San Diego, CA); streptavidin (SA)-CyChrome and SA-PE were obtained from

*Division of Developmental and Clinical Immunology, Departments of [†]Medicine, [‡]Pediatrics, and [§]Microbiology, University of Alabama, and the [¶]Howard Hughes Medical Institute, Birmingham, AL 35294; and [§]Washington University Center for Immunology and Department of Pathology, St. Louis, MO 63110.

Received for publication February 4, 2000. Accepted for publication June 12, 2000.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by National Institutes of Health Grant AI39816. R.G. was supported by a fellowship from the Human Frontier Science Program. M.D.C. is a Howard Hughes Medical Institute Investigator.

² Address correspondence and reprint requests to Dr. Max D. Cooper, University of Alabama, WTI 378, 1824 6th Avenue South, Birmingham, AL 35294-3300. E-mail address: Max.Cooper@ccc.uab.edu

³ Abbreviations used in this paper: BM, bone marrow; Jak, Janus-activated kinase; IFNAR, type I IFN receptor; SA, streptavidin; PI, phosphatidylinositol; GAF, IFN- γ activation factor; ISGF3, IFN-stimulated gene factor 3.

Southern Biotechnology Associates (Birmingham, AL). Cell suspensions were incubated on ice for 25 min with the FITC-, PE-, CyChrome-, or biotin-conjugated mAbs, washed with PBS containing 3% FCS and 0.02% NaN₃, and counterstained with SA-CyChrome or SA-PE to reveal biotin conjugates. Before analysis with a Becton Dickinson (Mountain View, CA) FACScalibur flow cytometer, 1 μ g/ml propidium iodide in PBS was added to allow identification of dead cells for exclusion from the analysis. The data was analyzed with the WinMDI 2.8 (Trotter@scripps.edu) software program.

Mice, cell lines, and IFN

Stat-1^{-/-} (22) and *Ifnar1*-deficient mice (B&K Universal Group, North Humberston, U.K.) were of 129SvEv background. Although the type I IFN receptor (IFNAR) is formed by two chains, IFNAR1 and IFNAR2, IFN- α -induced responses were undetectable in *Ifnar1*^{-/-} mice (16). *Stat-1* mice were bred as α -male \times β -female to derive α - and β -littermates. BALB/c mice were bred at our animal facility at the University of Alabama (Birmingham, AL). Four- to 6-wk-old animals were used as BM donors, and fetal liver cells were obtained 15 days postcoitus. *Stat-1* genotyping was conducted on DNA samples from tails or whole embryos, employing a PCR-based analysis with previously described primers (22).

The Scid7 IL-7-dependent cell line, a gift from Dr. S. I. Nishikawa (Kyoto University, Kyoto, Japan), has a pro-B phenotype (CD19⁺CD43⁺BP-1⁺ μ HC⁻) and is sensitive to IL-7 deprivation and the inhibitory effect of IFN- α (15).

An IFN- α and - β (IFN- $\alpha\beta$) combination isolated from viral-infected cultures and control supernatants from mock-infected cultures were purchased from Access Biomedical (San Diego, CA) and used at an equivalent concentration of 10³ U/ml.

Ex vivo B lymphopoiesis assay

BM mononuclear cells from 6- to 8-wk-old mice or fetal liver mononuclear cells from 15-day-old embryos were cultured with IL-7-transfected NIH3T3 fibroblasts (24) at a concentration of 10⁶ cells/ml in RPMI 1640 medium with 5% FCS, L-glutamine, penicillin/streptomycin, and 50 μ M 2-ME in the presence or absence of IFN- $\alpha\beta$. Ly294002 and wortmannin inhibitors were obtained from Calbiochem (La Jolla, CA). Cultured cells were harvested by treatment with 0.02% EDTA, and viable lymphoid cells were enumerated by phase microscopy on the basis of trypan blue exclusion.

Results

Assessment of B lymphopoiesis in *Stat-1*-deficient mice

Abnormalities of B lymphopoiesis have not been noted in *Stat-1*^{-/-} mice (22, 23), but a detailed analysis of B lineage development in these mice has not been reported. Therefore, in our initial studies, we examined B lineage cells for the expression of B220, CD19, CD43, BP-1, IgM, and IgD in BM samples from *Stat-1*^{-/-} mice and their α -littermate controls at 4–6 mo of age. This comparative analysis confirmed the expectation that B cell development occurs normally in *Stat-1*-deficient mice (data not shown).

Inhibition of B lymphopoiesis by type I IFNs in *Stat-1*-deficient mice

The possible role of *Stat-1* in the IFN- $\alpha\beta$ -mediated inhibition of B cell development was tested initially in an ex vivo system wherein progenitor cells from adult BM or fetal liver are cultivated with IL-7-transfected fibroblasts. In this ex vivo model, B220⁺ progenitor cells undergo proliferation and progressive differentiation into IgM⁺ B cells, whereas untransfected fibroblasts do not support B cell development (data not shown). Contrary to our expectation, in these experiments, the growth of B220⁺ B lineage cells was inhibited by IFN- $\alpha\beta$ treatment regardless of the *Stat-1* genotype. Comparable reductions in the numbers of viable B220⁺ cells were observed in IFN-treated cultures of cells from the *Stat-1*^{+/+} and *Stat-1*^{-/-} mice (Fig. 1). Phenotypic analyses over the 7-day culture interval further indicated comparable cellular composition of the surviving cell populations (Fig. 2). Notably, the development of μ HC⁺ pre-B and B cells was profoundly inhibited by IFN- $\alpha\beta$ regardless of whether the progenitor cells were obtained from *Stat-*




FIGURE 1. IFN- $\alpha\beta$ inhibition of IL-7-dependent B lymphopoiesis in *Stat-1*^{+/+} and *Stat-1*^{-/-} mice. *A*, Adult BM cells from *Stat-1*^{+/+} and *Stat-1*^{-/-} mice were cultured on IL-7-transfected fibroblasts for 4 days in the presence or absence of IFN- $\alpha\beta$. Viable cells were identified by trypan blue exclusion, counted, and the percentage of viable B lineage cells (B220⁺PI⁻) was determined by immunofluorescence flow cytometry. Results of three separate experiments are indicated. *B*, Progenitor cells in the liver of 15-day-old embryos, either *Stat-1*^{+/+} or *Stat-1*^{-/-}, were cultured and analyzed in the same manner as for BM cultures. Four embryos of each genotype were used in this experiment. These results were reproduced in five separate experiments. The numbers of B220⁺ cells (\pm SE) recovered per 10⁶ BM (*A*) or fetal liver (*B*) cells initially cultured are indicated (*, $p < 0.01$).

1^{+/+} or from *Stat-1*^{-/-} mice. The number of B220⁺ cells was also reduced by the IFN- $\alpha\beta$ treatment, although the limited growth of non-B lineage cells in this ex vivo system made it difficult to discern whether this was a primary or secondary effect. Titration of the IFN dosage resulted in a graduated decrease in the inhibition with lower concentrations, but differential levels of inhibition were not evident for the *Stat-1*^{+/+} and *Stat-1*^{-/-} cells at any IFN concentration (not shown). In keeping with previous results obtained for IL-7-dependent cell lines (15), the levels of IL-7R expression were not reduced after IFN- $\alpha\beta$ treatment, indicating that the inhibition cannot be explained simply by deprivation of the IL-7 signal (not shown).

To confirm the specificity of the IFN- $\alpha\beta$ inhibitory effect, we examined progenitor cells from mice deficient in the type I IFN receptor (*Ifnar1*^{-/-}). In these experiments, fetal liver cells from *Stat-1*^{+/+} and *Ifnar1*^{-/-} mice were cultured with the IL-7-producing fibroblasts either in the presence or absence of IFN- $\alpha\beta$. Whereas IFN- $\alpha\beta$ inhibited the development of *Stat-1*^{+/+} progenitors, the development of B lineage cells from the *Ifnar1*^{-/-} progenitors was unaffected by IFN- $\alpha\beta$ treatment (Fig. 3). These results indicate that the IFN- $\alpha\beta$ inhibitory effect is mediated specifically via the type I IFN receptor and cannot be attributed to a nonspecific toxin in the IFN- $\alpha\beta$ preparation.

Stat-1 is essential for the IFN- $\alpha\beta$ -mediated up-regulation of *Sca-1* in early B lineage cells

The foregoing evidence indicating that *Stat-1* is nonessential for the type I IFN-induced inhibition of IL-7-induced B lymphopoiesis was surprising, given that *Stat-1* is essential for all of the IFN- $\alpha\beta$ responses assessed in mature B cells (23). In view of this paradox,




FIGURE 2. IFN- $\alpha\beta$ -mediated inhibition of B lymphopoiesis in IL-7 supported cultures of fetal liver progenitors from *Stat-1*^{+/+} and *Stat-1*^{-/-} mice. Fetal liver cells were cultured on IL-7-transfected fibroblasts before harvesting for immunofluorescence analysis as in Fig. 1. The results of this experiment were confirmed in five separate experiments.

we examined whether Stat-1 was essential for another type of IFN response in the fetal liver progenitors, namely the up-regulation of transcription and expression of the Sca-1 Ag (Ly-6A/E), a cell surface accessory molecule expressed on BM and fetal liver cells (25, 26). When we examined Sca-1 expression by early B lineage cells, an IFN-induced up-regulation of this Ag could be easily detected for cells from the *Stat-1*^{+/+} mice, but not for cells from the *Stat-1*^{-/-} animals. IFN- $\alpha\beta$ also failed to enhance the expression of this Ag on cells from *Ifnar1*^{-/-} mice, thereby confirming the IFN- $\alpha\beta$ specificity of this response (Fig. 4). Therefore, this type I IFN response is *Stat-1*-dependent in B cell progenitors as is the case for B cells.

Evaluation of the role of phosphatidylinositol (PI) 3'-kinase in IFN- $\alpha\beta$ -mediated inhibition of B lymphopoiesis

PI 3'-kinase, which is involved in many signaling cascades that influence cell growth, is also activated following type I IFN stimulation (27–29). To examine its possible influence in the growth inhibition induced by IFN- $\alpha\beta$, we examined the role of PI 3'-kinase in the IFN-mediated inhibition of B lymphopoiesis. The initial assessment was conducted by adding Ly294002, an inhibitor of PI 3'-kinase (30), to cultures of fetal liver cells from BALB/c mice. Although relatively high concentrations of Ly294002 could inhibit B lymphopoiesis, this PI 3'-kinase inhibitor had no demonstrable counter effect on the IFN-mediated inhibition of cell growth at any of the concentrations employed (Fig. 5A). The effect of this PI 3'-kinase inhibitor was also evaluated in experiments in which an IL-7-dependent pro-B cell line, Scid7, was cultured with IL-7. In these experiments, the Scid7 cells were inhibited by IFN- $\alpha\beta$ at all inhibitor concentrations tested. Ly294002 alone was again inhibitory at the highest concentrations employed, but had no demonstrable counter effect on the IFN- $\alpha\beta$ -mediated inhibition (Fig. 5B). Wortmannin, another inhibitor of PI 3'-kinase, was also tested




FIGURE 3. Analysis of the IFN- $\alpha\beta$ effect on B lymphopoiesis in type I receptor-deficient mice (*Ifnar1*^{-/-}). Fetal liver cells from *Stat-1*^{+/+} and *Ifnar1*^{-/-} mice were cultured for 4 days in the presence or absence of IFN- $\alpha\beta$ before enumeration and immunofluorescence analysis as in Figs. 1 and 2. The results of this experiment were reproduced in three similar experiments.

in these experiments with the same outcome (data not shown). The inhibitory effect of Ly294002 alone, most evident at the highest concentration employed (1 μ M), can be attributed to the compromise of IL-7 signaling that involves PI 3'-kinase activity (10). If the IFN- $\alpha\beta$ -mediated inhibition of cell growth also required PI 3'-kinase activity, an increase would be expected in the numbers of cells treated with both IFN- $\alpha\beta$ and the inhibitor Ly294002. This outcome was not observed at any Ly294002 concentration, thereby suggesting that integrity of the PI 3'-kinase signaling pathway is not essential for the type I IFN-mediated inhibition of B lymphopoiesis.

Discussion

The present studies indicate that Stat-1 is not essential for the IFN- $\alpha\beta$ -mediated inhibition of B lymphopoiesis, in contrast with




FIGURE 4. Effect of IFN- $\alpha\beta$ treatment on Sca-1 expression by B lineage cells. Fetal liver cells from *Stat-1*^{+/+}, *Stat-1*^{-/-}, and *Ifnar1*^{-/-} mice were cultured for 4 days as indicated in Fig. 1 before immunofluorescence analysis of Sca-1 expression by B220+ cells.




FIGURE 5. Analysis of the effect of the PI 3'-kinase inhibitor, Ly290042, on IFN- α/β -mediated inhibition of B lymphopoiesis. *A*, Fetal liver progenitors from E15 BALB/c embryos were cultured for 3 days with IL-7-transfected fibroblasts before treatment for 2 days with the inhibitor at different concentrations, in the presence or absence of IFN. *B*, Scid7 cells were cultured for 4 days in IL-7-containing media with or without the inhibitor and IFN- α/β before enumeration and analysis as in previous figures. Cell numbers correspond to pooled cells from four separate cultures and are representative of two independent experiments.

previously described biological models wherein type I IFN-induced growth inhibition was abolished in Stat-1-deficient mice and cell lines (22, 23, 31).

Two major transcription factor complexes are formed in response to ligation of the type I IFN receptor: IFN- γ activation factor (GAF) and IFN-stimulated gene factor 3 (ISGF3) (17, 19, 20). GAF is a Stat-1 homodimer, whereas ISGF3 is formed by activated Stat-1, Stat-2, and p48 (32). Although Stat-1-deficient mice cannot form GAF, the possibility of a hypothetical ISGF3 complex lacking Stat-1 but still functional cannot be excluded for at least some responses. In this regard, we found that the expression of *Sca-1*, a gene containing targets for both GAF and ISGF3 factors in its promoter (26), was not up-regulated in B cell progenitors following IFN treatment of Stat-1-deficient mice.

The role of Stat-3 in type I IFN signaling is not as well documented as that for Stat-1 in part because the Stat-3 knockout is early embryonically lethal (33). Stat-3 may also be involved in the antiviral and antiproliferative activities of type I IFNs through up-regulation of NF- κ B binding activity (34) and by functioning as an adapter to couple PI 3'-kinase to the IFN receptor, thereby activating a new signaling pathway (28, 29). PI 3'-kinase is also associated with IL-7 receptor signaling, and its activity is required for the proliferative response of B cell progenitors (10). The essential role of this signaling component is evidenced by the block in B lymphopoiesis at the pro-B cell stage in PI 3'-kinase-deficient mice (35, 36). Using inhibitors of PI 3'-kinase, Ly294002 and wortmannin, we were unable to alter the inhibitory effect of IFN- α/β . Nevertheless, the possibility of competition between IL-7 and IFN signaling pathways for the available pool of PI 3'-kinase was not tested in these experiments.

The indication that Stat-1 is not essential for the inhibition of B lymphopoiesis by type I IFNs suggests that another, as yet uncharacterized, transcription complex (lacking Stat-1) or a different IFN signaling pathway is responsible for this inhibition of B cell development. Interferons can inhibit the growth of embryonic fibroblasts in a Stat-1-dependent fashion involving regulation of *c-myc*

expression. In this model system IFN- γ was recently shown to suppress *c-myc* expression in cells from wild-type mice, but not in those from Stat-1^{-/-} mice (37). Indeed, in the Stat-1-deficient cells both *c-myc* and *c-jun* expression were rapidly up-regulated in response to IFN- γ , thereby providing evidence for Stat-1-independent signaling in cells of another differentiation pathway.

As components of the innate immune system, IFNs are produced in response to external aggression (14). They also may be constitutively produced in a normal organism. IFN- β is one of many lymphopoietic regulatory factors (reviewed in Ref. 38) produced locally in normal BM (15), where it may play a role in selection of the B cell repertoire (39). Dissociation between the IFN-induced antiviral and growth signaling pathways has also been described (40). The complexity of the IFN signaling cascades, together with the results described above, suggest an interesting versatility in the signaling components responsible for the rich diversity of IFN responses. Elucidation of the Stat-1-independent pathway that is activated in early B lineage cells via the type I IFN receptor may also reveal the mechanism whereby this signaling pathway counteracts with that of the IL-7 receptor.

References

- Osmond, D. G., A. Rolink, and F. Melchers. 1998. Murine B lymphopoiesis: toward a unified model. *Immunol. Today* 19:65.
- Cooper, M. D., D. Mulvaney, A. Coutinho, and P. A. Cazenave. 1986. A novel cell surface molecule on early B-lineage cells. *Nature* 321:616.
- Hardy, R. R., C. E. Carmack, S. A. Shinton, J. D. Kemp, and K. Hayakawa. 1991. Resolution and characterization of pre-B and pre-pro-B cell stages in normal mouse bone marrow. *J. Exp. Med.* 173:1213.
- Allman, D. M., S. E. Ferguson, V. M. Lentz, and M. P. Cancro. 1993. Peripheral B cell maturation. II. Heat-stable antigen (hi) splenic B cells are in immature developmental intermediate in the production of long-lived marrow-derived B cells. *J. Immunol.* 151:4431.
- Karasuyama, H., A. Kudo, and F. Melchers. 1990. The proteins encoded by the V_{H} and $\lambda 5$ pre-B specific genes can associate with each other and with μ heavy chain. *J. Exp. Med.* 172:969.
- Coffman, R. L., and I. L. Weissman. 1983. Immunoglobulin gene rearrangement during pre-B cell differentiation. *J. Mol. Cell. Immunol.* 1:31.
- Vitetta, E. S., and J. W. Uhr. 1976. Cell surface immunoglobulin. XV. The presence of IgM and an IgD-like molecule on the same cell in murine lymphoid tissue. *Eur. J. Immunol.* 6:140.
- Namen, A. E., S. Lumpton, K. Hjerrild, J. Wignall, D. Y. Mochizuki, A. Schmierer, B. Mosley, C. J. March, D. Urdal, and S. Gillis. 1988. Stimulation of B-cell progenitors by cloned murine interleukin-7. *Nature* 333:571.
- Sudo, T., S. Nishikawa, N. Ohno, N. Akiyama, M. Takamashi, H. Yohida, and S. I. Nishikawa. 1993. Expression and function of the interleukin 7 receptor in murine lymphocytes. *Proc. Natl. Acad. Sci. USA* 90: 9125.
- Corcoran, A. E., F. M. Smart, R. J. Cowling, T. Crompton, M. J. Owen, and A. P. Venkataraman. 1996. The interleukin-7 receptor α chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis. *EMBO J.* 15:1924.
- Ihle, J. N. 1995. Cytokine receptor signaling. *Nature* 377:591.
- Von Freuden-Jeffry, U., P. Vieira, L. A. Lucian, T. McNeil, S. E. G. Burdack, and R. Murray. 1995. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a non-redundant cytokine. *J. Exp. Med.* 181:1519.
- Peschon, J. J., P. J. Morrissey, K. H. Grabstein, F. J. Ramsdell, E. Maraskovsky, B. C. Gliniak, L. S. Park, S. F. Ziegler, D. E. Williams, and C. B. Ware. 1994. Early lymphocyte expansion is severely impaired in interleukin-7 receptor-deficient mice. *J. Exp. Med.* 180:1955.
- Thomson, A. W., ed. 1998. *The Cytokine Handbook*. Academic Press, San Diego, CA.
- Wang, J., Q. Lin, H. Langston, and M. D. Cooper. 1995. Resident bone marrow macrophages produce type I interferons that can selectively inhibit interleukin-7 driven growth of B lineage cells. *Immunity* 3:475.
- Lin, Q., C. Dong, and M. D. Cooper. 1998. Impairment of T and B cell development by treatment with a type I interferon. *J. Exp. Med.* 187:79.
- Darnell, J. E. 1997. Stats and gene regulation. *Science* 277:1630.
- Pellegrini, S., and I. Dusanter-Fourt. 1997. The structure, regulation and function of the Janus kinases (Jaks) and the signal transducers and activators of transcription (Stats). *Eur. J. Biochem.* 248:615.
- Liu, K. D., S. L. Gaffen, and M. A. Goldsmith. 1998. Jak/Stat signaling by cytokine receptors. *Curr. Opin. Immunol.* 10:271.
- Haque, S. J., and B. R. G. Williams. 1998. Signal transduction in the interferon signal. *Semin. Oncol.* 25:14.
- Foxwell, B. M., C. Beadling, D. Guschin, I. Kerr, and D. Cantrell. 1995. Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine cells. *Eur. J. Immunol.* 25:3041.
- Meraz, M. A., J. M. White, K. C. F. Snee, E. A. Bach, S. J. Rodig, A. S. Digne, D. H. Kaplan, J. K. Rhee, A. C. Greenlund, D. Campbell, et al. 1996.

- Targeted disruption of the *Stat-1* gene in mice reveals unexpected physiologic specificity in the Jak-Stat signaling pathway. *Cell* 84:431.
23. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse *Stat-1* gene results in compromised innate immunity to viral disease. *Cell* 84:443.
 24. Borzillo, G. V., K. Endo, and Y. Tsujimoto. 1991. Bcl-2 confers growth and survival advantage to interleukin 7-dependent early pre-B cells which become factor independent by a multistep process in culture. *Oncogene* 7:869.
 25. Spangrude, G. J., and D. M. Brooks. 1993. Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly6A/E by bone marrow cells. *Blood* 82:3327.
 26. Khodadoust, M. M., K. D. Khan, E. Park, and A. L. M. Bothwell. 1998. Distinct regulatory mechanisms for interferon- α/β (IFN- α/β) and interferon- γ -mediated induction of Ly-6E gene in B cells. *Blood* 92:2399.
 27. Cantley, L. C., K. R. Auger, C. Carpenter, B. Duckworth, A. Graziani, R. Kapeller, and S. Soltoff. 1991. Oncogenes and signal transduction. *Cell* 64:281.
 28. Pfeffer, L. M., J. E. Mullersman, S. R. Pfeffer, A. Murti, W. Shi, and C. H. Yang. 1997. Stat3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. *Science* 276:1418.
 29. Uddin, S., E. N. Fish, D. A. Sher, C. Gardziola, M. F. White, and L. C. Platanias. 1997. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN- α . *J. Immunol.* 158:2390.
 30. Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *J. Biol. Chem.* 269:5241.
 31. Bromberg, J. F., C. M. Horvath, Z. Wen, R. D. Schreiber, and J. E. Darnell, Jr. 1996. Transcriptionally active Stat-1 is required for the antiproliferative effects of both interferon α and interferon γ . *Proc. Natl. Acad. Sci. USA* 93:7637.
 32. Qureshi, S. A., M. Salditt-Georgieff, and J. E. Darnell. 1995. Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. *Proc. Natl. Acad. Sci. USA* 92:3829.
 33. Takeda, K., K. Noguchi, W. Shi, T. Tanaka, M. Matsumoto, N. Yoshida, T. Kishimoto, and S. Akira. 1997. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. *Proc. Natl. Acad. Sci. USA* 94:3801.
 34. Yang, C. H., Murti A., and L. M. Pfeffer. 1998. Stat3 complements defects in an interferon-resistant cell line: evidence for an essential role for Stat3 in interferon signaling and biological activities. *Proc. Natl. Acad. Sci. USA* 95:5568.
 35. Fruman, D. A., S. B. Snapper, C. M. Yballe, L. Davidson, J. Y. Yu, F. W. Alt, and L. C. Cantley. 1999. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85 α . *Nature* 393:393.
 36. Suzuki, H., Y. Terauchi, M. Fujiwara, S. Aizawa, Y. Yazaki, T. Kadowaki, and S. Koyasu. 1999. Xid-like immunodeficiency in mice with disruption of the p85 α subunit of phosphoinositide 3-kinase. *Nature* 393:390.
 37. Ramana, C. V., N. Grammatikakis, M. Chernov, H. Nguyen, K. C. Gieh, B. R. Williams, and G. R. Stark. Regulation of *c-myc* expression by IFN- γ through Stat-1 dependent and -independent pathways. *EMBO J.* 19:263.
 38. Kincade, P. W. 1994. B lymphopoiesis: global factors, local control. *Proc. Natl. Acad. Sci. USA* 91:2888.
 39. Vasconcellos R., D. Braun, A. Coutinho, and J. Demengeot. 1999. Type I IFN sets the stringency of B cell repertoire selection in the bone marrow. *Int. Immunol.* 11:279.
 40. Arora, T., G. Floyd-Smith, M. J. Espy, and D. F. Jelinek. 1999. Dissociation between IFN- α induced anti-viral and growth signaling pathways. *J. Immunol.* 162:3289.

Associate Editor

Thomas J. Gill III

EDITORIAL



Fuller W. Bazer, Jr.

Type I Conceptus Interferons: Maternal Recognition of Pregnancy Signals and Potential Therapeutic Agents

FULLER W. BAZER AND HOWARD M. JOHNSON

Departments of Animal Science and Pediatrics (F.W.B.) and
Department of Microbiology and Cell Science (H.M.J.), University of
Florida, Gainesville, Florida

Establishment of pregnancy requires that the conceptus (embryo and its associated membranes) secrete products (e.g., steroids, proteins or prostaglandins) that affect the corpus luteum (CL) directly as a luteotrophic signal (e.g., chorionic gonadotrophin), as a luteal protective signal (e.g., prostaglandin (PG)E₂), or indirectly through antiluteolytic signals that inhibit uterine production of luteolytic amounts of PGF_{2α} to insure maintenance of corpus luteum function. Type I conceptus interferons secreted by trophoblast of sheep, cow, and goat are antiluteolytic signals responsible for maternal recognition of pregnancy that act locally on the uterine endometrium to suppress release of luteolytic amounts of PGF_{2α} (PGF).¹

Type I conceptus interferons have high amino acid sequence homology with both interferon alpha II (IFN α II) and omega interferon (IFN ω).²⁻⁴ Pig conceptuses secrete

both IFN α and IFN gamma (IFN γ).⁵ However, their role in the establishment of pregnancy has not been determined.⁶ Type I conceptus interferons produced by sheep, cow, and goat are called ovine trophoblast protein-1 (oTP-1), bovine trophoblast protein-1 (bTP-1) and caprine trophoblast protein-1 (cTP-1), respectively and they share considerable amino acid and nucleotide sequence homology.¹ Since the mechanisms involved in maternal recognition of pregnancy are similar for sheep, cow, and goat, this editorial will focus on oTP-1 and its role in establishment of pregnancy in sheep, as well as properties of oTP-1 that may be of therapeutic value in human and veterinary medicine.

oTP-1 is the major protein secreted by sheep conceptuses between days 12–21 of gestation that has antiluteolytic activity and the following properties¹: (1) Mr = 19,000 kDa; (2) 3 to 4 isoelectric variants with pI values between 5.4 and 5.6; (3) nonglycosylated; (4) does not stimulate cAMP, cGMP, or inositol phospholipid-diacylglycerol second messenger systems; (5) no chorionic gonadotrophin or lactogenic biological activities; (6) potent antiviral activity; (7) high amino acid sequence homology with IFN α II and IFN ω ; (8) binds to endometrial receptors, and (9) amplifies secretion of at least 11 endometrial proteins. oTP-1 is secreted by conceptuses as early as days 8 or 10, with rapid increases (ng/uterine flushing) as conceptuses change from spherical (312 ng) to tubular (1,380 ng) to filamentous forms (4,455 ng) on day 13⁷ and maximum secretion (100,000 to 150,000 ng) occurs between days 14 and 16.⁸

MATERNAL RECOGNITION OF PREGNANCY

The endometrium of cyclic ewes is stimulated by progesterone to increase phospholipid stores and cyclooxygenase enzymatic activity necessary for uterine production of luteolytic pulses of PGF, which cause structural and functional demise of the CL in cyclic ewes.⁹ Actual release of luteolytic pulses of PGF, however, does not occur in cows¹⁰ and pigs¹¹ until after endometrial progesterone receptors (PR) decrease, presumably due to progesterone-induced down-regulation of its own receptor¹ during late diestrus. In cows, the decrease in endometrial PR is followed by a rapid increase in numbers of endometrial receptors for oxytocin (OT-R).¹⁰ Estrogen, acting through its receptor (ER) appears to up-regulate endometrial OT-R.^{12,13} Endometrial ER and PR, depending upon stage of the menstrual cycle or estrous cycle, may be located in either epithelial or stromal cells of endometrium¹⁴; however, data are not available to indicate their location in sheep endometrium during the estrous cycle or pregnancy. With increased numbers of endometrial OT-R, oxytocin from the corpus luteum and/or posterior pituitary stimulates endometrial release of luteolytic pulses of PGF¹² acting through the inositol phospholipid protein kinase C (IP₃) second messenger system.¹⁵

Pregnancy results in significantly lower numbers of endometrial OT-R.¹⁵ Endometrial release of luteolytic pulses of PGF is suppressed and endometrium of pregnant ewes does not release luteolytic pulses of PGF in response to exogenous estradiol and oxytocin that do induce premature luteolysis in cyclic ewes.^{1,16} However,

Reproduction

Address reprint requests to Dr. Fuller W. Bazer, Animal Science Department, Building 459—Shealy Drive, University of Florida, Gainesville, FL 32611.

the endometrium of pregnant ewes does release higher basal amounts of PGF than cyclic ewes.

Intrauterine infusion of highly purified oTP-1 alone on days 12 through 14 extends luteal lifespan in cyclic ewes from about 19 days to 28 days and inhibits endometrial secretion of PGF in response to both exogenous E and OT.¹ Recent studies with recombinant oTP-1 (roTP-1) confirmed that oTP-1 is the only antiluteolytic protein required for extension of CL function in sheep.^{17,35} What is the mechanism of antiluteolytic biological activity of oTP-1? Endometrium from day 15 of the estrous cycle has high numbers of OT-R and oTP-1 receptors and has been used to demonstrate that oTP-1 does not inhibit binding of oxytocin to OT-R, oxytocin stimulation of its second messenger system, or oxytocin-induced secretion of PGF by endometrium.¹ These results suggest that initiation of secretion of oTP-1 by days 10–13 and initial intrauterine injections of oTP-1 on days 12–13 for cyclic ewes are necessary to actually inhibit synthesis of endometrial OT-R and suppress uterine release of luteolytic pulses of PGF. This is consistent with the fact that lower numbers of endometrial OT-R are detectable at this stage of early pregnancy.¹⁵

Intrauterine injections of 100 µg/day of highly purified oTP-1 on days 12 through 14 of the estrous cycle, i.e., beginning prior to OT-R formation, does inhibit development of endometrial OT-R as measured directly¹⁶ or indirectly.¹⁹ We are currently testing the hypothesis that oTP-1 either stabilize or up-regulate endometrial PR to prevent synthesis of OT-R and suppress release of luteolytic pulses of PGF. Preliminary results indicate that oTP-1 treatment of endometrium from cyclic ewes increases endometrial PR by about 40%.¹ Results from the cow, with total RNA from endometrium collected on days 10, 15, and 18 of the estrous cycle and pregnancy subjected to dot blot analysis with a cDNA probe for avian PR, indicated that steady-state levels of PR mRNA decrease between days 15 and 18 of the estrous cycle, but remain constant between days 10 and 18 of pregnancy (R.D. Geisert, C. Hostetler, F.W. Bazer, and R.C.M. Simmen, unpublished results). We hypothesize that bTP-1 is responsible for stabilization of the endometrial PR and failure of endometrium of pregnant cows to synthesize OT-R.¹ Others have determined that Type I interferons decrease receptors for estrogen and increase receptors for progesterone in tumors.^{20,21} Effects of Type I trophoblast interferons on endometrial ER and PR, their location (epithelium vs stroma) and levels of ER and PR mRNAs are being determined.

Endometrial epithelial cells from day 15 cyclic ewes in culture secrete PGF in response to oxytocin; an in vitro effect inhibited by exposure of the cells to oTP-1 for 24 h prior to treatment with oxytocin.²² A report²³ that oTP-1 and rIFN α attenuate basal production of PGF by endometrial cells cultured in vitro is not consistent with the fact that basal production of PGF is higher in pregnant than cyclic ewes¹ or with other in vivo and in vitro results.²² The IFN α signal transduction system includes activation of phospholipase A₂, which would be expected to increase arachidonic acid production²⁴ and synthesis of PGF. This may explain higher basal rates of secretion of PGF by endometrium of pregnant ewes and day 16 cyclic ewes exposed to oTP-1 in vitro.¹

Temporal changes in endometrial PR during the es-

trous cycle and early pregnancy of sheep have not been described. However, endometrial PR and ER in cyclic ewes decrease after day 12 of the cycle and endometrial ER are lower for pregnant ewes on days 9–15.²⁵ Endometrial PR and ER decrease after day 13 of the bovine¹⁰ and porcine¹¹ estrous cycle and, in cows, endometrial OT-R increase after the PR decline¹⁰ as our model predicts. We hypothesize that down-regulation of PR is a prerequisite for up-regulation of OT-R and that oTP-1 and other Type I conceptus interferons stabilize or up-regulate PR to inhibit OT-R synthesis and pulsatile secretion of PGF.

High affinity, low capacity binding sites for oTP-1 are present in endometrial membranes,²⁶ which also competitively bind rIFN α and rhIFN α .²⁷ Unoccupied oTP-1 receptors are similar for cyclic and pregnant ewes on days 8–12, but decrease thereafter for pregnant ewes, presumably because of increased binding of endogenous oTP-1²⁸ or, alternatively, because of a decrease in total numbers of oTP-1 receptors. Sheep endometrium may have high and low affinity receptors for oTP-1, but only high affinity receptors for rIFN α .²⁹ Antiluteolytic effects of oTP-1 may require binding to both types of receptor. If so, this would explain why oTP-1 has potent antiluteolytic activity that is not shared equally with rIFN α and rhIFN α .^{30,31} However, antiviral,³² immunosuppressive,³³ and antiproliferative³⁴ properties appear to be shared equally by oTP-1, rhIFN α , and rIFN α .

THERAPEUTIC VALUE

What is the potential therapeutic value of oTP-1? In order to answer that question it is necessary to have sufficient amounts of oTP-1 for clinical studies. To accomplish this goal a synthetic gene for oTP-1 was constructed using 11 pairs of complementary oligonucleotides containing 17 unique restriction enzyme sites spaced evenly throughout the coding region.³⁵ A SacII SalI fragment containing the entire open reading frame of oTP-1 was cloned in frame with a synthetic yeast ubiquitin (Ub) gene in the yeast expression plasmid pBS24Ub and named PBS24UboTP71. *S. cerevisiae* strain AB116 was then transformed with PBS24UboTP71. After a 36 h incubation of yeast strain AB116³⁴ containing PBS24UboTP71, approximately 100 mg soluble roTP-1 per liter of culture medium was obtained. The roTP-1 comigrated with native oTP-1 on 15% SDS polyacrylamide gels, exhibited immunological identity with natural oTP-1 using both polyclonal and monoclonal (HL98 2C6 3E3) antibodies to native oTP-1, and exhibited 0.6×10^6 antiviral units/mg compared to $0.7-2 \times 10^6$ antiviral units/mg for native oTP-1.³⁶

The antiviral activity of oTP-1 is as potent as that of known rIFN α s, but oTP-1 does not exert the cytotoxic effects characteristic of treatment with rhIFN α and rIFN α .^{34,36} In studies of human and feline peripheral lymphocytes infected with HIV and FIV, respectively, oTP-1 exhibited no cytotoxic effects at concentrations up to 200,000 antiviral units/ml, whereas rIFN α and rIFN α exerted cytotoxic effects at 1,000 to 5,000 antiviral units/ml.

oTP-1 also has anticellular activity that is equivalent to or greater than that of rIFN α and rhIFN α .³⁴ When anticellular activities of oTP-1, rIFN α , and rhIFN α were compared using human amnion (WISH) and Madin-Darby bovine kidney (MDBK) cells, all inhibited progression of the cells through the S phase, but oTP-1 was more

effective at lower dosages. Also, oTP-1, at 50,000 antiviral units/ml, stopped cell proliferation without effects on cell viability, while rIFN α , at the same concentration of antiviral activity, caused massive cell death.

Patients having steroid-dependent mammary tumors respond to treatment with IFN β because it increases PR and decreases ER in tumor cells.³⁷ Our preliminary results indicate that oTP-1 also increases PR¹ and endometrial PR are lower in pregnant ewes.²⁵ The potential therapeutic uses of oTP-1 in treatment of patients with steroid-dependent tumors is deserving of intensive studies.

Patients suffering from infection with HIV or diseases such as hairy cell leukemia are willing to consider life-long therapy; however, chronic IFN α treatment results in development of resistance to the effects of currently available recombinant IFN α s.³⁸ In addition, high doses of rIFN α s produce intolerable fever and chills, anorexia, weight loss, and fatigue³⁹ and they may also cause seizures.⁴ Interferons have both immunoenhancing and cytotoxic effects which require that therapeutic doses be chosen that favor the immunoenhancing effects of the drug. Type I trophoblast interferons act through receptors on the uterine epithelium, which is in direct contact with the trophoblast. However, cytotoxic effects of these Type I trophoblast interferons on uterine epithelium exposed to as much as 40 million units of antiviral activity per 24 h have not been detected. This led to our working hypothesis that the Type I trophoblast interferons, such as oTP-1, may have unique "cell friendly" properties that will make them especially useful interferons for therapeutic purposes.

A number of diseases affecting animals result from infections by retroviruses of the family Retroviridae and of the family Lentiviridae, such as the immunodeficiency viruses. These include ovine progressive pneumonia virus (OPPV), caprine arthritis-encephalitis virus (CAEV), feline immunodeficiency virus (FIV), equine infectious anemia (EIA), and feline immunodeficiency virus (FIV).⁴⁰ These diseases caused by OPPV, CAEV, and FIV, for example, are uniquely suited for testing the therapeutic value of oTP-1 in the control of immunodeficiency diseases because conceptuses of each of these species secrete Type I trophoblast interferons that have very high (80% or more) amino acid sequence homology with oTP-1. These animal models may be especially useful for assessing the therapeutic value of oTP-1 in preventing or ameliorating vertical and horizontal transmission of these viruses, as well as the efficacy of oTP-1 in treating infected fetuses.

SUMMARY

In summary, Type I conceptus interferons of sheep, goats, and pigs (perhaps all ruminants), which signal maternal recognition of pregnancy, may be useful for enhancing fertility in animal agriculture and may have potential in human and veterinary medicine as well. The Type I conceptus interferons share antiviral, anticellular, and immunosuppressive properties with Type I leukocyte interferons, but lack their cytotoxic effects, which may make them especially useful as therapeutic agents in human and veterinary medicine. The unique N-terminal structure of oTP-1 may account for its distinctive biological properties,⁴¹ including its antiluteolytic activity.⁴²

ACKNOWLEDGMENTS

This paper is published as University of Florida, Agricultural Experiment Station Journal Series No. R-01568. Research from our laboratories has been supported by NIH Grants HD 10436 and HD26006 and U.S.D.A. Grant 89-37240-4638.

REFERENCES

1. Bazer FW, Thatcher WW, Hansen PJ, Miranda MA, Ott TL, Piente C. Physiological mechanisms of pregnancy recognition in ruminants. *J Reprod Fertil* 1991; Suppl. 43:39-47.
2. Capon DJ, Shepard HM, Goeddel DV. Two distinct families of human and bovine interferon- α genes are coordinately expressed and encode functional polypeptides. *Mol Cell Biol* 1985; 5:768-779.
3. Hauptman R, Swetly P. A novel class of human Type 1 interferons. *Nucleic Acid Res* 1985; 13:4739-4749.
4. Roberts RM, Klemann SW, Leaman DW, Bixby JA, Cross JC, Farin CE, Imakawa K, Hansen TR. The polypeptides and genes for ovine and bovine trophoblast protein-1. *J Reprod Fertil* 1991; Suppl. 43:3-12.
5. La Bonnairdiere C, Martinat-Botte F, Terqui M, Lefevre F, Zouari K, Martal J, Bazer FW. Production of two species of interferon by Large White and Meishan pig conceptuses during the peri-attachment period. *J Reprod Fertil* 1991; 91:469-478.
6. Harney JP, Bazer FW. Effect of porcine conceptus secretory proteins on interestrus interval and uterine secretion of prostaglandins. *Biol Reprod* 1989; 41:277-284.
7. Nephew KP, McClure KE, Ott TL, DuBois DH, Bazer FW, Pope WF. Relationship between variation in conceptus development and differences in estrous cycle duration in ewes. *Biol Reprod* 1991; 44:536-539.
8. Ashworth CA, Bazer FW. Changes in ovine conceptus and endometrial function following asynchronous embryo transfer or administration of progesterone. *Biol Reprod* 1989; 40:425-433.
9. Eggleston DL, Wilken C, Van Kirk EA, Slaughter RG, Ji TT, Murdoch WJ. Progesterone induces expression of endometrial messenger RNA encoding for cyclooxygenase in sheep. *Prostaglandins* 1990; 39:675-683.
10. Myer HHD, Mittermeier Th, Schams D. Dynamics of oxytocin, estrogen and progesterone receptors in the bovine endometrium during the estrous cycle. *Acta Endocrinologica, Copenh* 1988; 118:96-104.
11. Deaver DR, Guthrie HD. Cytoplasmic estrogen receptor, estradiol and progesterone concentrations in endometrium of nonpregnant and pregnant pigs. *Biol Reprod* 1980; 23:72-77.
12. Flint APF, Sheldrick EL, McCann TJ, Jones DSC. Luteal oxytocin: characteristics and control of synchronous episodes of oxytocin and PGF $_{2\alpha}$ secretion at luteolysis in ruminants. *Domestic Anim. Endocrinol* 1990; 7:111-124.
13. Lanming GE, Vallet JL, Flint APF. Progesterone control of endometrial oxytocin receptor determines cycle length in sheep. *J Reprod Fertil* 1991; Suppl. 43:53-54.
14. Brenner RM, West NB. Estrogen and progesterone receptors in the reproductive tract of male and female primates. *Biol Reprod* 1990; 42:11-19.
15. Flint APF, Sheldrick EL. Ovarian oxytocin and maternal recognition of pregnancy. *J Reprod Fertil* 1986; 76:831-839.
16. Burgess KM, Ralph MM, Jenkin RG, Thorburn GD. Effect of oxytocin and estradiol on uterine prostaglandin release in nonpregnant and early-pregnant ewes. *Biol Reprod* 1990; 42:822-835.
17. Martal J, Degryse E, Charpigny G, Assal N, Reinaud P, Charlier M, Gave P, Lecocq JP. Evidence for extended maintenance of the corpus luteum by uterine infusion of a recombinant trophoblast α -interferon/trophoblastin in sheep. *J Endocrinol* 1991; 127:R5-R8.
18. Miranda MA, Harney JP, Ott TL, Bazer FW. Ovine trophoblast protein-1 reduces endometrial receptor binding capacity during early pregnancy in ewes. (unpublished results).
19. Miranda MA, Ott TL, Harney JP, Bazer FW. Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes. *Biol Reprod* 1990; 43:1070-1078.
20. Dimitrov NV, Meyer CJ, Strander H, Einhorn S, Cantell H. Interferons as a modifier of estrogen receptors. *Annals Clin. Lab Sci* 1984; 14:32-39.
21. Kauppila A, Cantell K, Janne O, Kokko E, Vihko E. Serum, sex steroid and peptide hormone concentrations and endometrial estrogen and progesterone receptor levels during administration of human leukocyte interferon. *Int J Cancer* 1982; 29:291-294.
22. Danet-Desnoyers G. Etude in vitro du mode d'action d'un interferon.

- embryonnaire la trophoblastine (oTP) inhibe les synthèses de prostaglandine F2 α dans les cellules endométriales. 1989; Master of Science Thesis. Université de Paris VI. Pierre et Marie Curie. Paris, France.
23. Salamonsen LA, Manikhot J, Healy DL, Findlay JK. Ovine trophoblast protein-1 and human interferon alpha reduce prostaglandin synthesis by ovine endometrial cells. *Prostaglandins*. 1989; 38:289-305.
 24. Hannigan GE, Williams BRG. Signal transduction by interferon- α through arachidonic acid metabolism. *Science*. 1991; 251:204-207.
 25. Findlay JK, Clarke IJ, Swaney J, Coivin N, Doughton B. Oestrogen receptors and protein synthesis in caruncular and intercaruncular endometrium of sheep before implantation. *J Reprod Fertil*. 1982; 64:329-339.
 26. Godkin JD, Bazer FW, Roberts RM. Ovine trophoblast protein-1, an early secreted blastocyst protein, binds specifically to uterine endometrium and affects protein synthesis. *Endocrinology*. 1984; 114:120-130.
 27. Stewart HJ, McCann SHE, Barker PJ, Lee KE, Lamming GE, Flint APF. Interferon sequence homology and receptor binding activity of ovine trophoblast antiluteolytic protein. *J Endocrinol*. 1987; 115:R13-R15.
 28. Knickerbocker JJ, Niswender GD. Characterization of endometrial receptors for ovine trophoblast protein-1 during the estrous cycle and early pregnancy in sheep. *Biol Reprod*. 1989; 40:361-370.
 29. Hansen TR, Kazemi M, Keisler DH, Malathy PV, Imakawa K, Roberts RM. Complex binding of the embryonic interferon, ovine trophoblast protein-1, to endometrial receptors. *J Interferon Res*. 1989; 9:215-225.
 30. Stewart HJ, Flint APF, Lamming GE, McCann SHE, Parkinson TJ. Antiluteolytic effects of blastocyst-secreted interferon investigated in vitro and in vivo in the sheep. *J Reprod Fertil*. 1989; Suppl 37:127-138.
 31. Davis MA, Ott TL. Comparison of effects of recombinant human interferon alpha II and ovine conceptus secretory proteins on the interstrous interval of sheep. *Biol Reprod*. 1989; 40:Suppl 1, 85 (abstr.).
 32. Pontzer CH, Torres BZ, Vallet JL, Bazer FW, Johnson HM. Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1. *Biochem Biophys Res Commun*. 1988; 152:801-807.
 33. Newton GR, Vallet JL, Hansen PJ, Bazer FW. Inhibition of lymphocyte proliferation by ovine trophoblast protein-1 and a high molecular weight glycoprotein produced by preimplantation sheep conceptus. *Am J Reprod Immunol*. 1989; 19:99-107.
 34. Pontzer CH, Bazer FW, Johnson HM. Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. *Cancer Res*. 1991; In Press.
 35. Ott TL, Van Hecke G, Johnson HM, Bazer FW. Cloning and expression in *S. cerevisiae* of a synthetic gene for the pregnancy recognition hormone ovine trophoblast protein-1: purification and antiviral activity. *Mol Endocrinol*. 1991; Submitted.
 36. Bazer FW, Johnson HM, Yamamoto JK. Effect of ovine trophoblast protein-1 on replication of the feline and human immunodeficiency viruses. *Biol Reprod*. 1989; 40: Suppl 1, 63 (abstr.).
 37. DeCicco F, Sica G, Benedetto MT, Ciabattini G, Rossiello F, Nicosia A, Lup G, Iacopino F, Mancuso S, Dell'Acqua S. In vitro effects of β -interferon on steroid receptors and prostaglandin output in human endometrial adenocarcinoma. *J Steroid Biochem*. 1988; 30:359-362.
 38. Tamm I, Jasny BR, Pfeffer LM. Antiproliferative action of interferons. In: Pfeffer LM, ed. *Mechanisms of Interferon Actions*. Vol II pp 26-57. Boca Raton, FL: CRC Press, Inc.; 1987.
 39. Oldham RK. Biologicals for cancer treatment: interferons. *Hospital Practice*. 1985; 20:71-91.
 40. Janssen JLS, Berk L, Vermeulen M, Schalm SW. Seizures associated with low dose α -interferon. *The Lancet*. 1990; 336:1580.
 41. Haase AT. Pathogenesis of lentivirus infections. *Nature*. 1987; 322:130-136.
 42. Pontzer CH, Ott TL, Bazer FW, Johnson HM. Localization of an antiviral site on the pregnancy recognition hormone, ovine trophoblast protein-1. *Proc Nat Acad Sci*. 1990; 87:5945-5949.
 43. Schalue TK, Miranda MA. Effects of intrauterine infusion of synthetic peptides corresponding to the c- and n-terminus of ovine trophoblast protein-1 (oTP-1) on oxytocin-induced endometrial phosphate metabolism in ewes. *Biol Reprod*. 1991; 44: Suppl 1.

The anti-tumor activities of interferon (IFN)- α in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN- α subtypes

Yoshiaki Yanai*, Osamu Sanou, Kouzou Yamamoto, Hiroshi Yamauchi,
Hakuo Ikegami, Masashi Kurimoto

Fujisaki Institute, Hayashibara Biochemical Laboratories, Inc., 675-1 Fujisaki, Okayama 702-8006, Japan

Received 30 April 2002; received in revised form 9 May 2002; accepted 9 May 2002

Abstract

Here we report on the anti-tumor effects of five interferon (IFN)- α subtypes, $\alpha 1$, $\alpha 2$, $\alpha 5$, $\alpha 8$, and $\alpha 10$ in chronic myelogenous leukaemia (CML)-derived cell lines. All of the CML cells can respond to IFN- α although the anti-tumor effects of IFN- α depend on the target cell and on the type of IFN- α subtype used. Proliferation assays showed that IFN- $\alpha 8$ was substantially more effective than the other four IFN- α subtypes. IFN- $\alpha 8$ was the most potent at upregulating immunomodulatory molecule expression while IFN- $\alpha 1$ was least potent. These data indicate in vitro distinctions between IFN- α subtypes that should be appreciated more in the clinic. © 2002 Elsevier Science Ireland Ltd. All rights reserved.

Keywords: Interferon (IFN)- α ; IFN- $\alpha 8$; Subtype; Chronic myelogenous leukaemia (CML); Fas

1. Introduction

Chronic myelogenous leukaemia (CML) is a cancer of the bone marrow, and is thought to arise as a direct result of the bcr-abl fusion-gene (Philadelphia chromosome positive; Ph(+)) due to translocation between chromosomes 9 and 22 [1–3]. The mechanisms favoring the growth advantage of Ph(+) cells over normal cells in CML are not fully elucidated but could be due partly to altered apoptosis and longer survival of CML clones. The BCR-ABL oncoprotein is a constitutively active protein tyrosine kinase, which plays a key role in the pathogenesis of the chronic phase of CML. It has been shown that the

increased tyrosine kinase activity of BCR-ABL is a requirement for transformation and is specific to leukemia cells, and can therefore be used as a sensitive marker of the disease through molecular biology techniques. Three phases of disease activity are recognized in CML; chronic phase, accelerated phase, and blast crisis. Like many chemotherapeutic agents (e.g. members of the tyrphostin family, herbimycin A and the 2-phenylaminopyrimidine STI 571) in the CML diseases, type I interferons (IFN- α/β) have a number of therapeutic applications in the treatment of various human cancers and diseases of viral origin [3,4]. IFN- α/β play a prominent role in the control of cellular proliferation and survival as well as having potent immunomodulatory and anti-angiogenic actions. Like most human cytokines, human IFN- β is encoded by a single gene, however human IFN- α comprises a

* Corresponding author. Tel.: +81-86-276-3141; fax: +81-86-276-6885.

E-mail address: fujisaki@hayashibara.co.jp (Y. Yanai).

large family of structurally related genes expressing at least fourteen subtypes and all are on chromosome 9. The coding regions of the IFN- α genes are quite similar, and the least related are about 77% homologous [5–7]. Recent studies have clarified to some extent the biological properties of the different IFN- α subtypes and the synthesis of the different IFN- α subtypes depends on the cell type and on the IFN- α inducer used [8–10]. Despite these studies, the physiological significance of the existence of so many IFN- α subtypes remains unknown and requires addressing.

In this report, we have examined the differential responsiveness to IFN- α subtypes to six well-characterized CML-derived cell lines: Ku-812, KYO-1, MEG-O1, NALM-1, PL-21, and U-937, respectively. In particular, we have evaluated the different IFN- α subtypes for their abilities to alter cell proliferation and modulation of the level of apoptosis. We have also investigated the induction of cell surface immunomodulatory molecules, including the human leukocyte antigen (HLA) class I antigen, Fas (CD95) and FasL by the IFN- α subtypes.

2. Materials and methods

2.1. Cell lines

The CML-derived cell lines, Ku-812 [11], KYO-1 [12], MEG-O1 [13], NALM-1 [14], PL-21 [15] and U-937 [16] cell were obtained from Fujisaki Cell Center of Hayashibara Biochemical Laboratories, Inc. Each cell line was grown in a culture medium consisting of Rosewell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% foetal calf serum (FCS), 100 U/ml penicillin, and 50 mg/ μ l streptomycin. Cells were cultured for 24 h before the experiments to allow the cells to enter their logarithmic growth phase.

2.2. IFN- α

Recombinant human IFN- α 1, 2, 5, 8, and 10 were prepared via the pET-3a – BL21 system (Novagen, WI, USA) as described previously [17]. The specific activities were 3.0×10^6 IU/mg for subtype α 1, 7.2×10^7 IU/mg for α 2, 4.0×10^7 IU/mg for α 5, 2.9×10^8 IU/mg for α 8 and 4.9×10^7 IU/mg for α 10. As regards IFN- α 2, because of glycosylation

of the naturally occurring subtype that may influence its biologic activity, we also purified natural IFN- α 2 from cultures of BALL-1 cells stimulated with Sendai virus instead of producing a recombinant product.

2.3. Growth inhibition assay

Cells of different lines were seeded at 1×10^3 – 5×10^3 cells/well in 96-well plates in RPMI 1640 medium supplemented with 10% FCS. IFN- α was added at the indicated concentrations (10 – 2×10^4 IU/ml). After 96 h, the medium was removed and the viable cells were counted using a cell-counting kit (Doujin Chemical Co., Tokyo, Japan). Triplicate wells were analyzed for each time point and IFN- α dosage. The 50% effective dose of antiproliferative effects (ED50) was estimated by Probit analysis.

2.4. Cell cycle analysis

Cell cycle analysis was carried out according to standard methods [17]. Briefly, cells of different lines were cultured at 10^4 cells/ml in RPMI 1640 medium containing 10% FCS and were left untreated or were treated with IFN- α (1000 IU/ml) for 96 h. Cells were harvested and fixed in 70% cold ethanol for 2 h. Fixed cells were stained with phosphate-buffered saline (PBS) (–) containing 40 μ g/ml propidium iodide for 15 min. Cell cycle and apoptosis were analyzed with an EPICS XL flow cytometer (Beckman coulter, CA, USA).

2.5. Analysis of expression of cell-surface antigens

Cells were left untreated or treated with IFN- α (100 IU/ml) for 48 h. Next, cells were collected and approximately 2×10^4 of the cells were stained in PBS with monoclonal antibody to HLA class I molecules (#CN109; YLEM, Rome, Italy), Fas (CH-11; MBL, Tokyo, Japan) or FasL for 60 min at room temperature. The first antibody was labeled with a fluorescein isothiocyanate (FITC)-conjugated anti-murine antibody for 30 min. Cells were analyzed using a Becton Dickinson FACScan Flow cytometer using standard protocols.




Fig. 1. Growth inhibition effects of the five IFN- α subtypes on six CML-derived cell lines. Proliferation of human CML-derived cells treated with different concentrations of various IFN- α subtypes for 96 h. The bars show the mean ED50 for IFN- α induced growth inhibition.

3. Results and discussions

3.1. Anti-proliferative effects of IFN- α subtypes on CML cell lines

The growth inhibitory effects of five IFN- α subtypes on the various CML-derived cell lines were analyzed (Fig. 1). Proliferation assays showed that sequential addition of IFN- α significantly increased growth inhibition except in PL-21 cells. The degree of sensitivity varied for each cell line. Both KYO-1 cells and U-937 cells were approximately 10-fold sensitive than the other lines in the order U-937 > KYO-1 > Ku-812 = MEG-O1 = NALM-1 \gg PL-21. In five of the cell lines tested, IFN- α 8 was substantially more effective than the other four IFN- α subtypes while IFN- α 1 was the least effective. Ku-812 cells and U-937 cells, in particular, proliferated at low concentrations of IFN- α 8 whereas any of the other IFN- α subtypes resulted in a reduction of cell growth by approximately 10%. IFN- α 8 was at least ten times more effective than IFN- α 1 in all the cell lines tested, suggesting that natural preparations with a high content of IFN- α 8 would be more effective than preparations with lower levels of IFN- α 8.

Interestingly, we also found a difference between the effects of the recombinant and natural IFN- α 2

(Fig. 2). Anti-proliferative effects of both recombinant and natural IFN- α 2 depend on the target cell lines. These differences appear to be correlated with the glycosylation of the naturally occurring subtype to some extent, however, what effects the modification of glycosylation of the mature form of native IFN- α 2 have on its function are still unknown. Several groups reported that IFN- α 8 may use IFNAR1 in a different fashion and make use of separate signal transduction pathways [18,19]. Recent studies revealed that IFNAR messenger RNA expression correlated with the response to IFN therapy and therefore, the dependency of IFN- α efficacy on the target cell and on the constituent IFN- α subtypes may be explained by differences in cell surface IFNAR expression on the different target cell lines used [20].

3.2. Measurement of IFN- α induced apoptosis of CML cells

To analyze IFN- α induced apoptosis in CML-derived cell lines, we next analyzed for changes in the cell cycle by measuring the cellular DNA contents (Fig. 3). When KYO-1, NALM-1 and U-937 cell were cultured for 96 h with IFN- α (10–1000 IU/ml), the frequency of the cells showing characteristic features




Fig. 2. Anti-proliferative effects of recombinant and natural IFN- α 2. Proliferation of human CML-derived cells treated with different concentrations of both recombinant IFN- α 2 (rIFN- α 2) and natural IFN- α 2 (nIFN- α 2) for 96 h. The bars show the mean ED50 for IFN- α induced growth inhibition.

of apoptosis tended to increase with IFN- α concentration. On the other hand, Ku-812, MEG-O1, and PL-21 cells were little affected by any of the IFN- α subtypes. Concerning growth inhibition activities, IFN- α 8 was 2–10-fold more potent than IFN- α 1, α 2, α 5, and α 10. However, this response appears to be unrelated to cell apoptosis.

Fas, one of the death-associated cell surface

proteins induced by IFN- α , can be triggered by an appropriate death-promoting ligand (FasL) to activate downstream caspases pivotal in initiation of programmed cell death [21,22]. We examined whether there were any changes in the cellular expression of Fas to reveal first insights into the changes in the mechanisms of IFN- α -induced apoptosis in vitro. KYO-1 cells and U-937 cells showed strong IFN- α -




Fig. 3. Analysis of IFN- α -induced apoptosis when treated with 1000 IU/ml IFN- α for 96 h. IFN- α induced apoptosis and cell cycle distribution was determined from the intensity of PI fluorescence.




Fig. 4. Induction of cell surface Fas antigen expression on U-937 cells treated with 100 IU/ml of the various IFN- α subtypes for 48 h. Shaded and white histograms represent KPK-13 cells treated with IFN- α and untreated cells, respectively (A) IFN- α 1; (B) IFN- α 2; (C) IFN- α 5; (D) IFN- α 8; and (E) IFN- α 10.

induced expression of Fas (Fig. 4). In particular, IFN- α 8 was the most effective immunomodulator and IFN- α 1 was the least potent. In addition, NALM

and MEG-O1 cells showed intermediate induction of Fas while Ku-812 and PL-21 cells were little affected by IFN- α . We also investigated the up-regu-




Fig. 5. Induction of cell surface HLA class I antigen expression on KYO-1 cells treated with 100 IU/ml of the various IFN- α subtypes for 48 h. Shaded and white histograms represent KYO-1 cells treated with IFN- α and untreated cells, respectively. (A) IFN- α 1; (B) IFN- α 2; (C) IFN- α 5; (D) IFN- α 8; and (E) IFN- α 10.

lation of FasL. However, only U-937 cells showed IFN- α 8-specific up-regulation of FasL, and IFN- α stimulation had a little effect on the expression levels when compared with unstimulated cells (data not shown). The differences in apoptosis induction could be correlated with the variations in death associated molecule expression of each cell line. Our results suggest that the Fas system may be one of the more important mechanisms of IFN- α specific induction of apoptosis in CML derived cell lines. The mechanisms underlying the cellular proliferative and apoptotic pathways involved are complex, with probable involvement of multiple protein networks/cascades.

3.3. IFN- α -induced upregulation of HLA class I expression

To examine the IFN- α induced expression of immunomodulatory molecules such as HLA class I on the CML cell surfaces, FACS analysis was employed. FACS analysis showed that IFN- α induced expression of the HLA class I in all of the six cells tested including PL-21 cells that are little affected as regards anti-proliferative effects, by any of the IFN- α subtypes. The degree of HLA class I upregulation varied for each cell line. In particular, KYO-1 cells and U-937 cells showed marked IFN- α induced enhanced expression of HLA class I molecules. The intensity of HLA class I expression was reflected by shifts in the mean fluorescence intensity as determined by the cytometer. On the IFN- α subtype level, IFN- α 2 and IFN- α 8 were the most effective immunomodulators (Fig. 5). Essentially the same results were obtained in studies using IFN- α subtypes on the other cell lines. Considerable attention has been focused on the ability of IFN- α to modulate cell surface antigen expression on a variety of human cells [23,24]. The ability of tumor cells to present tumor-associated antigens on the cell surface via HLA class I molecules is necessary for the generation of an effective specific anti-tumor antigen-directed CTL response. Because immunotherapy may be one of the most promising approaches for treating CML, understanding the mechanisms by which these tumors circumvent cytokine signaling, thereby evading anti-tumor specific antigen immunity, would greatly improve the efficacy of such therapy.

In summary, we have examined and estimated the

in vitro anti-tumor activities of five IFN- α subtypes on six CML cell lines. We found that in all of the six cell lines tested, IFN- α 8 was the most potent anti-tumor IFN- α subtype. Our results also imply that natural IFN- α preparations with high proportions of IFN- α 8 would be very effective anti-tumor agents. The importance of the existence of several IFN- α subtypes has yet to be fully appreciated, but uncertainties exist in many areas including the mechanism for the subtype-specific signaling pathways and different biological activities. Further study on the significance of IFN- α subtype function will be our future objective. In particular, IFN- α 8 can contribute to the further analysis of the physiological roles of IFN- α subtype-specific effects.

Acknowledgements

We would like to thank Mark J. Micallef, Ph. D., and Akira Harashima for valuable discussions on the manuscript.

References

- [1] E. Shtivelman, B. Lifshitz, R.P. Gale, E. Canaani, Fused transcript of *abl* and *bcr* genes in chronic myelogenous leukaemia, *Nature* 315 (1985) 550–554.
- [2] S. Faderl, M. Talpaz, Z. Estrov, H.M. Kantarjian, Chronic myelogenous leukemia: biology and therapy, *Ann. Intern. Med.* 131 (1999) 207–219.
- [3] S.J. Lee, Chronic myelogenous leukaemia, *Br. J. Haematol.* 111 (2000) 993–1009.
- [4] M.J. Mauro, B.J. Druker, Chronic myelogenous leukemia, *Curr. Opin. Oncol.* 13 (2001) 3–7.
- [5] S. Nagata, H. Tiara, A. Hall, L. Johnsrud, M. Streuli, J. Escordi, W. Bol, K. Cantell, C. Weissman, Synthesis in *E. coli* of a polypeptide with human leukocyte interferon activity, *Nature* 284 (1980) 316–320.
- [6] K. Henco, J. Brosius, J.I. Fujisawa, J.R. Haynse, J. Hochstadt, T. Kovacic, M. Pasek, A. Schambock, J. Schmid, K. Todorokoro, M. Walchli, S. Nagata, C. Weissmann, Structure relationship of human interferon gene and pseudogenes, *J. Mol. Biol.* 185 (1985) 227–260.
- [7] M.O. Diaz, S. Bohlander, G. Allen, Nomenclature of the human interferon genes, *J. Interferon Cytokine Res.* 16 (1992) 179–180.
- [8] F. Bisat, N.B. Raj, P.M. Pitha, Differential and cell type specific expression of murine alpha interferon genes is regulated on the transcriptional level, *Nucleic Acids Res.* 16 (1988) 6067–6083.
- [9] T.A. Nyman, H. Tolo, J. Parkkinen, N. Kalkkinen, Identifica-

- tion of nine interferon- α subtypes produced by Sendai virus-induced human peripheral blood leucocytes, *Biochem. J.* 329 (Pt 2) (1998) 295–302.
- [10] Y. Castelruiz, E. Larrea, P. Boya, M.P. Civeira, J. Prieto, Interferon alpha subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls, *Hepatology* 29 (1999) 1900–1904.
- [11] K. Kishi, M. Takahashi, S. Aoki, K. Nagai, H. Hirose, T. Koike, C. Sakai, Y. Aoyagi, M. Sanada, Y. Moriyama, A new Ph1 positive cell line (KU812) from a patient with blastic crisis of chronic myelogenous leukemia, *Nippon Ketsueki Gakkai Zasshi* 47 (1984) 709–718.
- [12] T. Ohkubo, T. Kamamoto, K. Kita, A. Hiraoka, Y. Yoshida, H. Uchino, A novel Ph1 chromosome positive cell line established from a patient with chronic myelogenous leukemia in blastic crisis, *Leuk. Res.* 9 (1985) 921–926.
- [13] M. Ogura, Y. Morishima, R. Ohno, Y. Kato, N. Hirabayashi, H. Nagura, H. Saito, Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome, *Blood* 66 (1985) 1384–1392.
- [14] J. Minowada, T. Tsubota, M.F. Greaves, T.R. Walters, A non-T, non-B human leukemia cell line (NALM-1): establishment of the cell line and presence of leukemia-associated antigens, *J. Natl. Cancer Inst.* 59 (1977) 83–87.
- [15] I. Kubonishi, K. Machida, H. Sonobe, Y. Ohtsuki, T. Akagi, I. Miyoshi, Two new human myeloid cell lines derived from acute promyelocytic leukemia and chronic myelocytic leukemia, *Gann* 74 (1983) 319–322.
- [16] C. Sundstrom, K. Nilsson, Establishment and characterization of a human histiocytic lymphoma cell line (U-937), *Int. J. Cancer* 17 (1976) 565–577.
- [17] Y. Yanai, O. Sanou, T. Kayano, H. Ariyasu, K. Yamamoto, H. Yamauchi, H. Ikegami, M. Kurimoto, Analysis of the antiviral activities of natural IFN- α preparations and their subtype compositions, *J. Interferon Cytokine Res.* 10 (2001) 835–841.
- [18] M. Schwabe, G.L. Princler, C.R. Faltynek, Characterization of the human type I interferon receptor by ligand blotting, *Eur. J. Immunol.* 18 (1988) 2009–2014.
- [19] J.R. Cook, C.M. Cleary, T.M. Mariano, L. Izotova, S. Pestika, Differential responsiveness of a splice variant of the human type I interferon receptor to interferons, *J. Biol. Chem.* 271 (1996) 13448–13453.
- [20] K.E. Mogensen, M. Lewerenz, J. Reboul, G. Lutfalla, G. Uze, The type I interferon receptor: structure, function, and evolution of a family business, *J. Interferon Cytokine Res.* 19 (1999) 1069–1098.
- [21] J.W. Greiner, P.B. Fisher, S. Pestka, J. Schlom, Differential effects of recombinant human leukocyte interferons on cell surface antigen expression, *Cancer Res.* 46 (1986) 4984–4990.
- [22] H. Kazama, S. Yonehara, The mechanism and regulation of Fas-mediated apoptosis, *Seikagaku* 73 (2001) 107–110.
- [23] S. Ferrone, F.M. Marincola, Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance, *Immunol. Today* 16 (1995) 487–494.
- [24] F. Garrido, F. Ruiz-Cabello, T. Cabrera, J.J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen, P.L. Stern, Implication for immunosurveillance of altered HLA class I phenotypes in human tumors, *Immunol. Today* 18 (1997) 89–95.